Advanced search
Publication Cover
Drug Metabolism Reviews Volume 29, 1997 - Issue 1-2
Submit an article Journal homepage
8,024
Views
881
CrossRef citations to date
0
Altmetric
Original Article

Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors

Slobodan Rendic Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biochemistry University of Zagreb, PB 156, A. Kovacica 1, HR-10000, Zagreb, Croatia
&
Frederick J. Di Carlo HERD 7403 U.S. Environmental Protection Agency, 401 M Street, SW, Washington, DC, 20460, USA
Pages 413-580 | Published online: 15 Feb 2010

References

  • Generic F. P. Stockholm P450: Advances and prospects. FASEB J. 1992; 6: 667–668, F. P. Guengerich, Human cytochrome P450 enzymes, Life. Sci., 50, 1471–1478 (1992); M. J. Coon, X. Ding, S. J. Pernecky, and A. D. N. Vaz, Cytochromes P450: Progress and predictions, FASEB J., 6, 669–673 (1992); R. W. Estabrook, The remarkable P450s: A historical overview of these versatile hemoprotein catalysts, FASEB J., 10, 202–204 (1996); F. J. Gonzales and Y. H. Lee, Constitutive expression of hepatic cytochrome P450 genes, FASEB J., 10, 1112–11127 (1996)
  • Black S. D. Membrane topology of the mamalian P450 cytochromes. FASEB J. 1992; 6: 680–685, E. F. Johnson, T. Kronbach, and M.-H. Hsu, Analysis of the catalytic specificity of cytochrome P450 enzymes through site-directed mutagenesis, FASEB J., 6, 700–705 (1992); T. L. Poulos and R. Raag, Cytochrome P450cam: Crystallography, oxygen activation, and electron transfer, FASEB J., 6, 674–679 (1992); D. F. V. Lewis, Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450 102 (P450bm3), Xenobiotica, 25, 333–366 (1995); D. F. V. Lewis, Molecular modeling of CYP1A subfamily members based on an alignment with CYP102: Rationalization of CYP1A substrate specificity in terms of active site amino acid residues, Xenobiotica, 26, 723–753 (1996)
  • Guengerich F. P. Human cytochrome P450 enzymes. Cytochrome P450—Structure, Mechanism and Biochemistry, 2nd ed., P. R. Ortiz de Montellano. Plenum Press, New York 1995; 473–535
  • Kronbach T. Hepatic microsomes and drug-metabolising enzymes. Pharmacokinetics, Regulatory-Industrial-Academic Perspectives, 2nd ed, P. G. Welling, F. L. S. Tse. Marcel Dekker, New York 1995; 236–253
  • Spatzeneger M., Jaeger W. Hepatic P450 in drug metabolism. Drug Metab. Rev. 1995; 27: 397–417, R. Slaughter and D. J. Edwards, Recent advances: The cytochrome P450 enzymes, Pharmacokinetics, 29, 619–624 (1995)
  • Smith D. A., Jones B. C. Speculations on the structure-activity relationship (SAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 1992; 44: 2089–2098
  • Beaune P. H. Les cytochromes P450 humains. Therapie 1993; 48: 521–526
  • Graham-Lorence S., Peterson J. A. P450s: Structural similarities and functional differences. FASEB J. 1996; 10: 206–214
  • Guengerich F. P. Characterization of human cytochrome P450 enzymes. FASEB J. 1992; 6: 745–748, F. P. Guengerich, Catalytic selectivity of human cytochrome P450 enzymes: Relevance to drug metabolism and toxicity, Toxicol. Lett., 70, 133–138 (1994)
  • Smith D. A. Chemistry and enzymology: Their use in the prediction of human drug metabolism. Eur. J. Pharm. Sci. 1994; 2: 69–71
  • Caldwell J. Cytochrome P450, In vitro drug metabolism studies in drug development and registration. Pharmaceutical Forum 1995; 4: 5–9
  • Park B. K., Pirmohamed M., Kitteringham N. R. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol. Ther. 1995; 68: 385–424
  • Yang C. S., Brady J. F., Hong J.-Y. Dietary effects on cytochromes P450, xenobiotic metabolism, and toxicity. FASEB J. 1992; 6: 737–744
  • Pessayre D. Cytochromes P450 et formation de metabolites reactifs. Therapie 1993; 48: 537–548, A. J. Paine, Heterogeneity of cytochrome P450 and its toxicological significance, Hum. Exp. Toxicol., 14, 1–7 (1995)
  • Ortiz de Montellano P. R. Cytochrome P450 catalysis: Radical intermediates and dehydrogenation reactions. TIPS Rev. 1989; 10: 354–359
  • Shimada T., Yamazaki H., Mimura M., Wakamiya N., Ueng Y. F., Guengerich F. P., Inui Y. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. 1996; 24: 515–522
  • Schmider J., Greenblatt D. J., von Moltke L. L., Harmatz J. S., Duan S. X., Karsov D., Shader R. I. Characterization of six in vitro reactions mediated by human cytochrome P450 directed antibodies. Pharmacology 1996; 52: 125–134, S. Ono, T. Hatanaka, H. Hotta, T. Satoh, F. J. Gonzalez, and M. Tsutsu, Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes, Xenobiotica, 26, 681–693 (1996)
  • Koymans L., Donne-Op den Kelder-Koppele G. M., Koppele Te J. M., Veremeulen N. P. E. Cytochromes P450: Their active site structure and mechanism of oxidation. Drug Metabol. Rev. 1993; 25: 325–387
  • Guengerich F. P. Bioactivation and detoxication of toxic and carcinogenic chemicals. Drug Metab. Dispos 1993; 21: 1–6, D. Mansuy, Cytochromes P-450 and model systems: Great diversity of catalyzed reactions, Pure Appl. Chem., 66, 737–744 (1994)
  • Jousserandot A., Boucher J.-L., Desseaux C., Delaforge M., Mansuy D. Formation of nitrogen oxides including NO from oxidative cleavage of C = N(OH) bonds: A general cytochrome P450 dependent reaction. Bioorg. Med. Chem. Lett. 1995; 5: 423–426, B. S. S. Masters, K. McMillan, E. A. Sheta, J. S. Nishimura, L. J. Roman, and P. Martasek, Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: Structure studies of a cysteine thiolate-liganded heme protein that hydroxylates l-arginine to produce NO as a cellular signal, FASEB J., 10, 552–558 (1996); A. Parkinson, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials, Toxicol. Pathol., 24, 45–57 (1996)
  • Goeptar A. R., Scheerens H., Vermulen N. P. E. Oxygen and xenobiotic reductase activities of cytochrome P450. Crit. Rev. Toxicol. 1995; 25: 25–65, H.-M. Peng, G. M. Raner, A. D. N. Vaz, and M. Coon, Oxidative cleavage of esters and amides to carbonyl products by cytochrome P450, Arch. Biochem. Biophys., 318, 333–339 (1995): M. J. Coon, A. D. N. Vaz, and L. L. Bestervelt, Peroxidative reactions of diversoenzymes, FASEB J., 10, 428–434 (1996)
  • Böcker T. H. Derivatives of 19-nortestosterone with closely related structure: Mechanism based inhibition of human liver cytochrome P450 3A and variation of inhibitory potency. ISSX Proceedings, 5th North American ISSX Meeting, Bal Harbour, FL, November, 2–61992. Vol. 2: 115, A. M. Batt, N. Strazielle, and G. Siegst, Induction and repression des cytochromes P450—Approche in vivo et in vitro, Therapie, 48, 527–536 (1993); J. R. Halpert, F. P. Guengerich, J. R. Bend, and M. A. Correia, Selective inhibitors of cytochromes P450, Toxicol. Appl. Pharmacol., 125, 163–175 (1994); I. I. Karuzina and A. I. Archakov, The oxidative inactivation of cytochrome P450 in monooxygenase reaction. Free Rad. Biol., 16, 93–97 (1994); J. R. Halpert, Structural basis of selective cytochrome P450 inhibition, Annu. Rev. Pharmacol. Toxicol., 35, 29–53 (1995); D. J. Newton, R. W. Wang, and A. Y. H. Lu, Cytochrome P450 inhibitors—evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver-microsomes, Drug Metab. Dispos, 23, 154–158 (1995); M. Bourrie, V. Meunier, Y. Berger, and G. Fabre, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes, J. Pharmacol. Exp. Ther., 277, 321–332 (1996)
  • Gibaldi M. Pharmacogenetics: Part I. Ann. Pharmacother. 1992; 26: 121–126, W. Taeschner and U. A. Meyer, Prediction of genetic variation of drug metabolism, Eur. J. Pharm. Sci., 2, 72–74 (1994); A. K. Daly, Molecular basis of polymorphic drug metabolism, J. Mol. Med., 73, 539–553 (1995); L. Bertilsson and M. L. Dahl, Polymorphic drug oxidation: Relevance to the treatment of psychiatric disorders, CNS Drugs, 5, 200–223 (1996)
  • Gibaldi M. Drug Interactions: Part I. Ann. Pharmacother. 1992; 26: 709–713
  • Gibaldi M. Pharmacogenetics: Part II. Ann. Pharmacother. 1992; 26: 255–261
  • Bock K. W., Schrenk D., Forster A., Griese E.-U., Morike K., Brockmeier D., Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferase in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994; 4: 209–218, A. Rannug, A. K. Alexandrie, I. Persson, and M. Inglemansundberg, Genetic polymorphism of cytochromes P450 1A1, 2D6, and 2E 1—Regulation and toxicological significance, J. Occup. Envir. Med., 37, 25–36 (1995)
  • Nebert D. W., Nelson D. R., Adesnik M., Coon M. J., Estabrook R. W., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Kemper B., Levin W., Phillips I. R., Sato R., Waterman M. R. The P450 superfamily: Updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 1989; 8: 1–13, D. W. Nebert, D. R. Nelson, M. J. Coon, R. W. Estabrook, R. Feyereisen, Y. Fujii-Kuriyama, F. J. Gonzalez, F. P. Guengerich, I. C. Gunsalus, E. F. Johnson, J. C. Looper, R. Sato, M. R. Waterman, and D. J. Waxman, The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature, DNA Cell Biol., 10, 1–14 (1991); D. R. Nelson, T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisen, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda, and D. W. Nebert, The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature, DNA Cell Biol., 12, 1–51 (1993)
  • Testa B. The metabolism of drugs and other xenobiotics. Biochemistry of Redox Reactions. Academic Press, New York 1995; 78–87
  • Nelson D. R., Koymans L., Kamataki T., Stegeman J. J., Feyereisen R., Waxman D. J., Waterman M. R., Gotoh O., Coon M. J., Estabrook R. W., Gunsalus I. C., Nebert D. W. The P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42
  • Doehmer J., Schneider A., Fassbender M., Soballa V., Schmalix W. A., Greim H. Genetically engineered mammalian cells and applications. Toxicol. Lett. 1995; 82/83: 823–827
  • Waterman M. R., Jenkins C. M., Pikuleva I. Genetically engineered bacterial cells and applications. Toxicol. Lett. 1995; 82/83: 807–813, D. F. Grant, J. F. Greene, F. Pinot, B. Borhan, M. F. Moghaddam, B. D. Hammockl, B. McCutchen, H. Ohkawa, G. Luo, and T. Guenther, Development of an in situ toxicity assay system using recombinant baculoviruses, Biochem. Pharmacol., 51, 503–515 (1996)
  • Gonzalez F. J., Korzekwa K. R. Cytochromes P450 expression systems. Annu. Rev. Toxicol. Pharmacol. 1995; 35: 369–390, S. Imaoka, T. Yamada, T. Hiroi, K. Hayashi, T. Sakaki, Y. Yabusaki, and Y. Funae, Multiple forms of human P450 expressed in Saccharomyces cerevisiae, systemic characterization and comparison with those in rat, Biochem. Pharmacol., 51, 1041–1050 (1996) F. J. Gonzalez and Y. H. Lee, Cytochromes P450.6. Constitutive expression of hepatic cytochrome P450 genes, FASEB. J., 10, 1112–1117 (1996)
  • Street J. C., Lee J. S., Jarema M. A. C. Study of coumarin metabolism by Chinese humster lung fibroplasts expressing a human cytochrome P450 using H-1-nmr. Xenobiotica 1996; 26: 447–457
  • Neal G. E. Genetic implications in the metabolism and toxicity of mycotoxins. Toxicol. Lett. 1995; 82/83: 861–867
  • Gonzalez F. J., Gelboin H. V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogenesis and toxins. Drug Metab. Rev. 1994; 26: 165–183, S. J. Roberts-Thompson, M. E. McManus, R. H. Tukey, F. J. Gonzales, and G. M. Holder, Metabolism of aza-aromatic carcinogens by four ex-pressed human cytochromes P450, Cancer Res., 55, 1052–1059 (1995)
  • Code E. L., Crespi C. L., Penman B. W., Gonzalez F. J., Chang T., Waxman D. J. Immunochemical and enzymatic characterization of human hepatic levels of CYP2B6. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September, 11995. Vol. 8: 100, S. Ekins, M. VandenBranden, B. J. Ring, and S. A. Wrighton, Kinetic and inhibition characteristics of CYP2B6, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, October 20–25, 1996, Vol. 9, p. 232
  • Lewis D. F. V., Ioannides C., Parke D. V. Molecular modeling of cytochrome CYPIAI: A putative access channel explains differences in induction potency between the isomers benzo[a]pyrene and benzo[e]pyrene, and 2- and 4-acetylaminofluorene. Toxicol. Len. 1994; 71: 235–243, D. F. V. Lewis, H. Moereels, B. G. Lake, C. loannides, and D. V. Parke, Molecular modeling of enzymes and receptors involved in carcinogenesis: QSARs and compact-3D, Drug Metabol. Rev., 26, 261–285 (1994); J. P. Jones, M. Shou, and K. R. Korzekwa, Stereospecific activation of the pro-carcinogen benzo[a]pyrene: A probe for the active sites of the cytochrome P450 superfamily, Biochemistry, 34, 6957–6961 (1995)
  • Wrighton S. A., Vanden Branden M., Stevens J. C., Shipley L. A., Ring B. J. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab. Rev. 1993; 25: 453–484
  • Ioannides C., Parke D. V. Induction of cytochrome P450 1 as an indictor of potential chemical carcinogenesis. Drug Metabol. Rev. 1993; 25: 485–501, M. R. Juchau, Q. P. Lee, and A. G. Fantel, Xenobiotic biotransformation/bioactivation in organogenesisstage conceptual tissues, Drug Metab. Rev., 24, 195–238 (1992)
  • Fijii-Kuriyama Y., Imataka H., Sogawa K., Yasumoto K.-I., Kikuchi Y. Regulation of CYPIAI expression. FASEB J. 1992; 6: 707–710, J. T. M. Buters, M. Shou, J. P. Hardwick, K. R. Korzekwa, and F. Gonzalez, Human CYPIAI: cDNA-directed expression using baculovirus, reconstitution of catalytic activity and metabolism of 7,12-dimethylbenz[a]nthracene, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 359
  • Rost K. L., Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin. Pharmacol. Ther. 1994; 55: 402–411, N. J. Cavuto, N. Sukhova, J. Hewett, J. D. Balian, R. L. Woosley, and D. A. Flockhart, Effects of omeprazole on theophylline clearance in poor metabolizers of omeprazole, Clin. Pharmacol. Ther., 57, 215 (0111–83) meeting abstract (1995)
  • Curi-Pedrosa R., Daujat M., Pichard L., Ourlin J. C., Clair P., Gervot L., Lesca P., Domergue J., Jpyeux H., Fourtainer G., Murel P. Omeprazole and lansprazole are mixed inducers of CYP1A and 3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 1994; 269: 384–392
  • Buening M. K., Chang R. L., Huang M.-T., Fortner J. G., Wood A. W., Conney A. H. Activation and inhibition of benzo[a]pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res. 1981; 41: 67–72
  • Siess M.-H., Leclerc J., Rat P., Suschetet M. vitro modulation of monooxygenase activities by natural flavonoids in human and rat liver. ISSX Proceedings, 5th European ISSX Meeting, ToursFrance, September, 26–291993. Vol. 3: 179
  • Li Y., Wang E., Patten C., Chen L., Yang C. S. Effects of flavonoids on cytochrome P450-dependent acetaminophen metabolism in rats and human liver microsomes. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, AZ, October, 17–211993. Vol. 4: 96, M. T. Obermeier, R. E. White, and C. S. Yang, Effects of biflavonoids on hepatic P450 activities, Xenobiotica, 25, 575–584 (1995); C.-H. Yun, H. G. Jeong, H. S. Lee, and F. P. Guengerich, In vivo and in vitro effects of myristicin on cytochrome P450 enzymes, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 55
  • Nelson S. D. Molecular mechanisms of the hepatotoxicity caused by acetminophen. Semin. Liver Dis. 1990; 10: 267–278, N. P. E. Vermeulen, J. G. M. Bessems, and R. Van der Straat, Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention, Drug Metab. Rev., 24, 367–407 (1992)
  • McLemore T. L., Adelberg S., Liu M. C., Mahon N. A., Yu S. J., Hubbard W. C., Czerwinski M., Wood T. G., Storeng R., Lubet R. A., Eggleston J. C., Boyd M. R., Hines R. N. Expression of CYPIAI gene in patients with lung cancer: Evidence for cigarette smoke-induced expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J. Natl. Cancer Inst. 1990; 83: 1333–1339, K. Kawajiri, K. Nakachi, K. Imai, J. Watanabe, and S. L. Hayashi, Crit. Rev. Oncol. Hematol., 14, 77–87 (1993)
  • Parke D., Ioannides C. The role of metabolic studies in the safety evaluation of new chemicals. Acta. Pharm. Jugosl. 1990; 40: 363–382
  • Yamazaki H., Mimura M., Oda Y., Gonzales F. J., El-Bayoumy K., Chae H. Y., Guengerich F. P., Shimada T. Activation of trans-1,2-dihydro-1,2-dihydro-1,2-hydroxy-6-aminochrysene to genotoxic metabolites by rat and human cytochromes P450. Carcinogenesis 1994; 15: 465–470
  • Pang S., Spink D. C. Effects of exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 and HEP G2 cells. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27- September, 11995. Vol. 8: 173, M. J. Sanstefano, U. Savas, C. R. Jefcoate, and L. S. Birnbaum, Time dependent regulation of CYP1A1, CYP1A2 and CYPIB1 protein expression by TCDD, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, October 20–25, 1996, Vol. 10, p. 157; F. Vecchini and S. Michel, Importance of cytochrome P450 for the development of new drug concepts in the skin, Eur. J. Dermatol., 4, 583–588 (1994); C. L. Hayes, D. C., Spink, B. C. Spink, J. Q. Cao, N. J. Walker, and T. R. Sutter, 17β-estradiol hydroxylation catalyzed by human cytochrome P450 1B1, Proc. Natl. Acad. Sci. USA, 74, 9776–9781 (1996); W. M. Tang, Y. Y. P. Wo, J. Stewart, A, L, Hawkins, C. A. Driffin, T. R. Sutter, and W. F. Greenlee, Isolation and characterization of the human cytochrome P450 CYP1B1 gene, J. Biol. Chem., 271, 28324–28330 (1996)
  • Bauer E., Guo Z., Ueng Y.-F., Bell L. C., Zeldin D., Guengerich F. P. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 1995; 8: 136–142
  • Kadlubar F. F. Biochemical individuality and its implications for drug and carcinogen metabolism: Recent insights from acetyltransferase and cytochrome P4501 A2 phenotyping in humans. Drug Metab. Rev. 1994; 26: 37–46
  • Tassaneeyakul W., Birkett D. J., Veronese M. E., McManus M. E., Tukey R. H., Quattrochi L. C., Gelboin H. V., Miners J. O. Specificity of substrate and inhibitor probes for human cytochromes P451A1 and 1A2. J. Pharmacol. Exp. Ther. 1993; 265: 401–407
  • Butler M. N., Iwasaki M., Guengerich F. P., Kadlubar F. K. Human cytochrome P-450PIA (P450IA2), the phenacetin O-deethylase, is primary responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA 1989; 86: 7696–7700, J. C. Bloomer, S. E. Clarke, and R. J. Chenery, Determination of P4501A2 activity in human liver microsomes using [3-14C-methyl caffeine, Xenobiotica, 25, 917–927 (1995)
  • Tassaneeyakul W., McManus M. E., Tasseneeyakul W., Veronese M. E., Andersson T., Tukex R. H., Miners J. O. Caffeine metabolism by human hepatic cytochromes P450: Contribution of 1A2, 2E3, and 3A isoforms. Biochem. Pharmacol. 1994; 47: 1767–1776, U. Jeppesen, S. Loft, H. E. Poulsen, and K. Brosen, A fluvoxamine-caffeine interaction study, Pharmacogenetics, 6, 213–222 (1996)
  • Butler M. A., Lang N. P., Yang J. F., Caporaso N. E., Vineis P., Hayes R. B., Teitel C. H., Massengill J. P., Lawsen M. F., Kadlubar F. F. Determination of CYP1A2 and NAT2 phenotypes in human populations by caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116–127, U. Fuhr, K. L. Rost, R. Engelhardt, M. Sachs, D. Liermann, C. Belloc, P. Beaunne, D. Janezic, D. Grant, U. A. Meyer, and A. H. Staib, Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations, Pharmacogenetics, 6, 159–176 (1996)
  • Notarriani L. J., Oliver S. E., Dobrocky P., Benett P. N., Silverman B. W. Caffeine as a metabolic probe—a comparison of the metabolic ratios used to assess CYP1A2 activity. Brit. J. Clin. Pharmacol. 1995; 39: 65–69, J. O. Miners and D. J. Birkett, The use of caffeine as a metabolic probe for human drug metabolising enzymes, Gen. Pharmacol., 27, 245–249 (1996)
  • Shaw L., Lennard M. S., Tucker G. T., Bax N. D. S., Wood H. F. Irreversible binding of propranolol by human liver microsomes—relationship to polymorphic oxidation. Biochem. Pharmacol. 1987; 36: 2283–2288, Y. Masubuchi, S. Hosokawa, T. Horie, T. Suzuki, S. Ohmori, M. Kitada, and S. Narimatsu, Cyotchrome P450 isoenzymes involved in propranolol metabolism in human liver-microsomes—the role of 2D6 as ring-hydoxylase and CYP1A2 as N-deisopropylase, Drug Metab. Disposition, 22, 909–915 (1994); K. Yoshimoto, H. Echizen, K. Chiba, M. Tani, and T. Ishizaki, Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers—desisopropylation is mediated mainly by CYP1A2, Br. J. Clin. Pharmacol., 39, 421–431 (1995); M. Ching, N. Bichara, C. L. Blake, H. Ghabrial, R. H. Tukey, and R. A. Smallwood, 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and 1A2, Drug Metab. Disposition, 24, 692–695 (1996)
  • Bourdi M., Timel M., Beune P. H., Pessayre D. Interactions of dihydralazine with cytochrome P4501A: A possible explanation for the appearance of anti-cytochrome P450 1A2 autoantibodies. Mol. Pharmacol. 1994; 45: 1287–1295
  • Buening M. K., Chang R. L., Huang M.-T., Former J. G., Wood A. W., Conney A. H. Activation and inhibition of benzo[ajpyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res. 1981; 41: 67–72
  • Kunze K. L., Trager W. F. Mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. ISSX Proceedings, 5th North American ISSX Meeting, Bal Harbour, FL, November, 2–61992. Vol. 2: 16, S. E. Clarke, A. D. Ayrton, and R. J. Chenery, Characterization of the inhibition of P450 1A2 by furafylline, Xenobiotica, 24, 517–526 (1994); J. K. Racha, A. E. Rettie, and K. L. Kunze, Mechanistic studies on the inactivation of human cytochrome P450 1A2 by furafylline, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, October 20–25, 1996, Vol. 10, p. 229; K. L. Kunze, J. K. Racha, and J. Calamia, Novel aspects of the oxidation of 8-ethyl xanthine analogs of furafylline by human P4501A2, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, October 20–25, 1996, Vol. 10, p. 230
  • Wei X., Thummel K. E., Banks R. C., Vestal R. E. Structure-related inhibitory potency of class IB antiarrhytmics mexiletine, lidocaine, and tocainide on in vitro human CYP1A2. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September, 11995. Vol. 8: 151
  • Ohashi K., Sakamoto K., Sudo T., Tateishi T., Fujimura A., Shiga T., Egihara A. Effects of diltiazem and cimetidine on theophylline oxidative metabolism. J. Clin. Pharmacol. 1993; 33: 1233–1237, R. G. Knodell, D. G. Browne, G. P. Gwozdz, W. R. Brian, and F. P. Guengerich, Differential inhibition of individual human liver cytochromes P450 by cimetidine, Gastroenterology, 101, 1680–1691 (1991); S. Toon, B. L. Holt, F. G. P. Mullins, and A., Kahn, Effects of cimetidine, ranitidine, and omeprazole on tolbutamide pharmacokinetics, J. Pharm. Pharmacol., 47, 85–88 (1995)
  • Fuhr U., Anders E.-M., Mahr G., Sörgel F., Staib A. H. Inhibitory potency of quinolone anibacterial agents against cytochrome P450 1A2 activity in vivo and in vitro. Antimicrob. Agents Chemother. 1992; 36: 942–948, Y. Mizuki, I. Fujiwara, K. Yamamoto, T. Yamaguchi, T. Fujii, and H, Miyazaki, Essential physiocochemical characteristics of enoxacin on inhibition of theophylline metabolism, ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October 23–27, 1994, Vol. 6, p. 140
  • Sandhu P., Guo Z., Baba T., Martin M. V., Tukey R. H., Guengerich P. F. Expression of modified human cytochrome P450 1A2 in Escherichia coli, stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Arch. Biochem. Biophys. 1994; 309: 168–177, C. W. Fisher, D. L. Caudle, C. Martin-Wixtrom, L. C. Quattrochi, R. H. Tukey, M. R. Waterman, and R. Estabrook, FASEB J., 6, 759–764 (1992); M. S. Shet, C. W. Fisher, and R. Estabrook, Expression, purification, and enzymatic properties of a recombinant fusion protein containing human P450 1A2 joined to NADPH-P450 reductase, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 362
  • Gallagher E. P., Wienkers L. C., Stapleton P. L., Kunzel K. L., Eaton D. L. Role of human microsomal and human complementary DNA-expressed cytochromes P450 1A2 and P450 3A4 in the bioactivation of aflatoxin B1. Cancer Res. 1994; 54: 101–108, Y. F. Ueng, T. Shimada, H. Yimazaki, and F. P. Guengerich, Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes, Chem. Res. Toxicol., 8, 218–225 (1995)
  • Roberts E. A., Xie Z. W., Yang S., Lipa J. Inducibility of enzyme activities associated with the cytochrome P450 1 A family, ethoxyresorufin O-deethylase, and methoxyresorufin O-demethylase in human hepatocyte lines derived from normal liver tissue. Drug Metab. Dispos 1993; 21: 56–61
  • Burke M. D., Thompson S., Weaver R. J., Wolf C. R., Mayer R. T. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 1994; 48: 923–936
  • Chang T. K. H., Gonzalez F. J., Waxman D. J. Evaluation of triacetoyloleandomycin. α-naftoflavone and diethyldithiocarbamate as selective chemical probe for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 1994; 311: 437–442
  • Madden S., Spaldin V., Hayes R. N., Wolf T. F., Pool W. F., Park B. K. Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 1995; 25: 103–116
  • Buening M. K., Fortner J. G., Kapas A., Conney A. H. 7,8-Benzoflavone stimulates the metabolic activation of aflatoxin B I to mutagens by human liver. Biochem. Biophys. Res. Commun. 1978; 82: 348–355
  • Yun C.-H., Shimada T., Guengerich F. P. Purification and characterization of human liver microsomal cytochrome P4502A6. Mol. Pharmacol. 1994; 40: 679–685, H. Yamazaki, T. Shimada, and F. P. Guengerich, Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P450 in liver microsomes of Japanese and Caucasian populations, Xenobiotica, 26, 395–403 (1996)
  • Patten C., Koch P. Baculovirus expression of human cytochrome P4502A6. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October, 23–271994. Vol. 6: 179, E. L. Code, W. T. Melvin, B. W. Penman, D. J. Waxman, and C. L. Crespi, Characterization of a monoclonal antibody selectively inhibitory to human CYP2A6, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 101; P. M. Fernandez-Salguero, S. M. G. Hoffman, S. Cholerton, H. Mohrenweiser, H. Raunio, O. Pelkonen, J.-D. Huang, W. E. Evans, J. R. Idle, and F. J. Gonzalez, A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2 genes and identification of variant CYP2A6 alleles, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 104; J. R. Tornton-Manning, J. A. Hotchkiss, X. Ding, and A. R. Dahl, Identification of CYP2A6 in human nasal respiratory mucosa and immunohistochemical localization of CYP2A in the rat nasal cavity, ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October 23–27, 1994, Vol. 6, p. 252
  • Cashman J. R., Yang Z.-C., Yang L., Wrighton S. A. Stereo- and regioselective N- and S-oxygenation of tertiary amines and sulfides in adult human liver microsomes. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, AZ, October, 17–211993. Vol. 4: 34
  • Kharasch E. D., Hankins D. C., Thummel K. Human kidney microsomal volatile anesthetic metabolism: Potential role in nephrotoxicity. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October, 23–271994. Vol. 6: 269
  • Eagling V. A., Howe J. L., Barry M. J., Back D. J. The metabolism of zidovudine by human liver microsomes in vitro: Formation of 3′-amino-3′-deoxythimidine. Biochem. Pharmacol. 1994; 48: 267–276, X.-R. Pan-Zhou, P. Maurel, and J.-P. Sommadossi, Reduction of AZT in human liver microsomes, Clin. Pharmacol. Ther., 55, 138 (PI60) meeting-abstract (1994); X.-R. Pan-Zhou, E. C. Scott, X.-J. Zhou, M.-X. Yang, J. M. Lasker, and J.-P. Sommadossi, Reductive metabolism of 3′-azido-3′-deoxythymidine by human liver: Involvement of microsomal P450, cytochrome b5, and their respective reductases, FASEB J., 9, A1487, meeting-abstract (1995)
  • Ring B. J., Binkley S. N., Vanden Branden M., Catlow J., Lindsay T. J., Gillespie T., Roskos L. K., Swanson S. P., Wrighton S. A. The use of in vitro methodologies to predict potential drug interactions with the antypsychotic drug olanzapine. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 60, B. J. Ring, S. N. Binkley, J. Catlow, T. J. Lindsay, T. Gillespie, L. K. Roskos, B. J. Cerimele, S. P. Swanson, M. A. Hamman, and S. A. Wrighton, Identification of the human P450 responsible for in vitro formation of the major oxidative metabolites of the antipsychotic drug olanzapine, J. Pharmacol. Exp. Ther., 276, 658–666 (1996)
  • de Morais S. M. F., Goldstein J. A. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1995; 4: 285–299, S. M. F. de Morais, U. A. Meyer, P. Linko, and J. A. Goldstein, CYP2C19 RNA level correlates with S-mephenytoin 4′-hydroxylase activity in human liver, ISSX Proceedings, Sixth North American ISSX Meeting, Raleigh, NC, October 23–27, 1994, Vol. 6, p. 239; T. H. Sullivan, B. I. Ghanayem, M. F. Faletto, and J. A. Goldstein, Comparison of mephenytoin 4′-hydroxylation by recombinant CYP2C19 and various 2C9 mutants constructed by site-directed mutagenesis, ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October 23–27, 1994, Vol. 6, p. 178; J. A. Goldstein, G. R. Wilkison, K. Nakamura, U. A. Meyer, and S. M. F. de Morais, Identification of the genetic defects responsible for the mephenytion 4′-hydroxylase polymorphism in humans, ISSX Proceedings, Sixth North American ISSX Meeting, Raleigh, NC, October 23–27, 1994, Vol. 6, p. 2
  • Heyn H., Stevens J. C., Marietta M. P. The N-demethylation of S-mephenytoin by cytochromes P450 2B6 and 3A4. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 73, 1995, H. Heyn, R. B. White, and J. C. Stevens, Catalytic role of cytochrome P4502B6 in N-demethylation of S-mephenytion, Drug Metab. Dispos., 24, 948–954 (1996)
  • Balian J. D., Sukhova N., Hewett J., Harris J. W., Woosley R. L., Flockhart D. A. Omeprazole: a probe for the S-mephenytion hydroxylation. Clin. Pharmacol. Ther. 1994; 55: 169, (PII-64) meeting-abstract
  • Caraco Y., Tateishi T., Wood A. J. J. Interethnic differences in omeprazole's inhibition of diazepam metabolism. Clin. Pharmacol. Ther. 1995; 58: 62–72
  • Caraco Y., Wilkinson G. R., Wood A. J. J. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A4 by omeprazole. Clin. Pharmacol. Ther. 1996; 60: 369–404, K.-U. Petersen, Review article: omeprazole and the cytochrome P450 system, Aliment. Pharmacol. Ther., 9, 1–9 (1995)
  • Miners J. O., Birket D. J. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytion hydroxylase and CYP3A isoforms. Clin. Pharmacol. Ther. 1994; 55: 138, (PI-59) meeting-abstract, S. Ono, T. Hatanaka, S. Miyzawa, M. Tsutsui, T. Aoyama, F. J. Gonzalez, and T. Satoh, Human liver microsomal diazepam metabloism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and 3A subfamily, Xenobiotica, 26, 1155–1166 (1996)
  • He M., Korzekwa K. R., Kunze K. L., Jones J. P., Trager W. F. Probing the active site of cytochrome P450—Metabolic and kinetic studies on a series of coumarin anticoagulants which serve as substrates/inhibitors of P4502C9. ISSX Proceedings, Sixth North American ISSX Meeting, Raleigh, NC, October, 23–271994. Vol. 6: 49
  • Lopez-Garzia P., Dansette P., Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochrome P450: In-activation of yeast expressed human liver cytochrome P450 2C9 by tienilic acid. Biochemistry 1994; 33: 166–175, J. O. Miners, D. L. P. Rees, L. Valente, M. E. Veronese, and D. J. Birket, Human hepatic cytochrome P-450 2C9 catalyses the rate-limiting pathway of torsemide metabolism, J. Pharmacol. Exp. Ther., 272, 1076–1081 (1995); P. Jean, P. Lopez-Garzia, P. Dansette, D. Mansuy, and J. L. Goldstein, Oxidation of tienilic acid by human yeast-expressed bytochromes P450 2C8, 2C9, 2C18 and 2C19, Evidence that this drug is a mechanism based inhibitor specific for cytochrome P450 2C9, Eur. J. Biochem., 241, 797–804 (1996)
  • Baldwin S. J., Bloomer J. C., Smith G. J., Airton A. D., Clarke S. E., Chenery R. J. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 1995; 25: 261–270
  • Miners J. O. In vitro approaches for prediction of oxidative drug metabolism in vivo. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August27-September, 11995. Vol. 8: 2, W. Tassaneeyakul, D. J. Birkett, J. W. Edvards, M. E. Veronese, W. Tassaneeyakul, R. Turkey, and J. O. Miners, Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m-, and p-xylene, J. Pharmacol. Exp. Ther., 276, 101–108 (1996)
  • Nielson K. K., Brosen K., Jeppe Hansen M. G., Gram L. F. Single dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin. Pharmacol. Ther. 1994; 55: 518–527, K. Kramer Nielsen, J. P. Linois, P. Beaune, and K. Brosen, The biotransformation of clomipramine in vitro, Identification of the cytochrome P450s responsibel for the sparteine metabolic pathyways, J. Pharmacol. Exp. Ther., 278, 1659–1664 (1996)
  • Bonnabry P., Leemann T., Dayer P. Biotransformation by hepatic P450TB (CYP2C) controls mefenamic elimination. Clin. Pharmacol. Ther. 1994; 55: 139, (PI66) meeting-abstract, P. Bonnabry, T. Leemann, and P. Dayer, Role of human liver cytochrome P450TB (2C9) in the biotransformation of lornixocam, Clin. Pharmacol. Ther., 57, 152 (PI-70) meeting-abstract (1995); T. S. Tracy, C. Marra, S. A. Wrighton, F. J. Gonzalez, and K. R. Korzekwa, Studies of flurbiprofen 4′-hydroxylation, Additional evidence suggesting the sole involvement of chtochrome P450 2C9, Biochem. Pharmacol., 52, 1305–1310 (1996); T. S. Tracy, B. W. Rosenbluth, S. A. Wrighton, F. J. Gonzalez, and K. R. Korzekwa, Role of cytochrome P4502C9 and an alleic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofen, Biochem. Pharmacol., 49, 1269–1275 (1995)
  • Vogt N., Leeman T., Dayer P. Transiet inhibition of P450TB (CYP2C) by fluvastatin in vivo. Clin. Pharmacol. Ther. 1994; 55: 154, (PII-5) meeting-abstract, C. Transon, T. Leemann, and P. Dayer, In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6, and CYP3A4) by HNG-CoA reductase inhibitors, Eur. J. Clin. Pharmacol., 50, 209–215 (1996)
  • Parkinson A. In vitro approach to studying human P450 enzymes. ISSX Proceedings, Sixth North American ISSX Meeting, Raleigh, NC, October, 23–271994. Vol. 6: 5
  • Karam W. G., Goldstein J. A., Lasker J. M., Ghanay G. I. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab. Dispos. 1996; 24: 1081–1087, G. C. Ibenau, B. I. Ghanayern, P. Linko, L. G. Pedersen, and J. A. Goldstein, Identification of residues 99, 220, and 221 of human cytochromne P4502C 19 as key determinants of omeprazole hydroxylase activity, J. Biol. Chem., 271, 12496–12501 (1996)
  • Andersson T., Miners J. O., Veronese M. E., Birkett D. J. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. 1994; 37: 597–604
  • Trager W. F. Stereoselectivity as an tool for identifying the enzymes controlling the clearance of chiral and prochiral drugs in vivo. ISSX Proceedings, 6th North American 1SSX Meeting, Raleigh, NC, October, 23–271994. Vol. 6: 30
  • Kitcen I., Tremblay J., Andrés J., Dring L. G., Idle J. R., Smith R. L., Williams R. T. Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 1979; 9: 397–404
  • Roy S. D., Hawes E. M., McKay G., Korchinski E. D., Midha K. K. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin. Clin. Pharmacol. Ther. 1985; 38: 128–133, S. Geertsen, B. C. Foster, D. L. Wilson, T. D. Cyr, and W. Casly, Metabolism of 2-methoxyphenamine and 2-methoxyamphetamine in 2D6-transfected cells and cell preparations, Xenobiotica, 25, 895–906 (1995)
  • Tucker G. T., Lennard M. S., Ellis S. W., Woods H. F., Cho A. K., Lin L. Y., Hiratsuka A., Schmitz D. A., Chu T. Y. Y. The demethylenation of methylenedioxymethamphethamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 1994; 47: 1151–1156
  • Ellis S. W., Ching M. S., Watson P. F., Henderson C. J., Simzula A. P., Lennard M. S., Tucker G. T., Woods H. F. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem. Pharmacol. 1992; 44: 617–620, E. M. J. Gillam, Z. Guo, M. V. Martin, C. M. Jenkins, and F. P. Guengerich, Arch. Biochem. Biophys., 319, 540–550 (1995); M. J. I. Paine, D. Gilham, G. C. K. Roberts, and C. R. Wolf, Functional high level expression of cytochrome P4502D6 using baculoviral expression systems, Arch. Biochem. Biophys., 328, 143–150 (1996)
  • Otton S. V., Schadel M., Cheung S. W., Kaplan H. L., Busto U. E., Sellers E. M. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 1993; 54: 463–472, H. K. Kroemer and M. Eichelbaum, Molecular bases and clinical consequences of genetic cytochrome P4502D6 polymorphysm, Life Sci., 26, 2285–2298 (1995); Z. R. Liu, O. Mortimer, C. A. D. Smith, C. R. Wolf, and A. Rane, Evidence for role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism, Br. J. Clin. Pharmacol., 39, 77–80 (1995)
  • Ducharme J., Abdullah S., Fried K., Wainer I. W. Dextromethorphan as an in vivo probe for CYP3A4 activity. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October, 23–271994, 240
  • Gorski J. C., Jones D. J., Wrighton S. A., Hall S. D. Characterization of dextromethorphan N-demethylation by human liver microsomes: Contribution of P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 1994; 48: 173–182, C. J. McIntyre, A. Madan, and A. Parkinson, Investigation of the role of CYP2B6 in the N-demethylation of dextromethorphan by human liver microsomes, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct. 20–25, Vol. 10, p. 231, 1996
  • Ωortimer U., Lindström B., Laurell H., Bergman U., Rane A. Dextromethorphan: Polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br. J. Clin. Pharmacol. 1989; 27: 223–227, M. Schadel, D. Wu, S. V. Otton et al., Pharmacokinetics of dextromethorphan and metabolites in humans: Influence of the CYP2D6 phenotype and quinidine inhibition, Can. J. Clin. Psychopharmacol., 15, 263–269 (1995)
  • Jaruratanasirikul S., Hortiwakul R. The inhibitory effect of amiodarone and desmethylamiodarone on dextromethorphan O-demethylation in human and rat liver microsomes. Clin. Pharmacol. Ther. 1994; 55: 169, (PII-65) meeting-abstract
  • Distlerath L. M., Guengerich F. P. Characterization of human liver cytochrome P450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Proc. Natl. Acad. Sci. USA 1984; 81: 7348–7352
  • Zekorn C., Achtert G., Hausleiter H. J., Moon C. H., Eichelbaum M. Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin. Wochenschr. 1985; 63: 1180–1186
  • Kharasch E. D., Thummel K., Mautz D., Bosse S. Clinical enflurane metabolism by cytochrome P4502E1. Clin. Pharmacol. Ther. 1994; 55: 434–440, K. J. Garton, J. Meinwald, K. E. Thumel, and E. Kharasch, Stereoselective metabolism of enflurane by human liver cytochrome P4502E1, Drug Metab. Dispos, 23, 1426–1430 (1996)
  • Kharasch E. D., Thummel K. Cytochrome P450 participation in human volatile anesthetic defluorination. ISSX Proceedings, 5th North American ISSX Meeting, Bal Harbour, FL, November, 2–61992. Vol. 2: 18, E. D. Kharasch, A. S. Armstrong, K. Gunn, A. Artru, K. Cox, and M. D. Karol, Clinical sevoflurane metabolism and disposition, 2: The role of cytochrome P450 2E1 in fluoride and hexafluorisopropanol formation, Anesthesiology, 82, 1379–1388 (1995)
  • Kenna J. G., Van-Pelt-Fnam. The metabolism and toxicity of inhaled anaesthetic agents. Anaesth.-Pharmacol. Rev. 1994; 2: 29–42, J. Gut, U. Christen, N. Frey, V. Koch, and D. Stoffler, Halothane hepatitis: Molecular mimicry between triflouroacetyl-adducts to proteins and lipoylated self components, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 235; E. D. Kharasch, K. Thummel, D. Hankins, and D. Mautz, Human oxidative halothane metabolism in vivo is catalyzed by P452E1, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 94; E. Eliasson, H. V. Hume-Smith, I. Gardber, and J. K. Kenna, Cytochrome P450 2E1 and halothane hepatitis, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 229
  • Koop D. R. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J. 1992; 6: 724–730, S. P. Carpenter and J. L. Raucy, CYP2E1: A putative role in chemical-mediated teratogenesis, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 238; J. L. Raucy, Risk assessment: Toxicity from chemical exposure resulting from enhanced expression of CYP2E1, Toxicology, 105, 217–224 (1995); M. J. Seaton, P. M. Schlosser, J. A. Bond, and M. A. A. Medinsky, Benzene metabolism by human liver microsomes in relation to cytochrome P4502E1, Carcinogenesis, 15, 1799–1806 (1994); T. Nakagawa, M. Sawada, F. J. Gonzalez, T. Yokoi, and T. Kamataki, Stable expression of human CYP2E1 in Chinese hamster cells: high sensitivity to N,N-dimethylnitrosamine in cytotoxycity testing, Mutat. Res., 354, 181–186 (1996)
  • Nakajima T., Wang R.-S. Induction of cytochrome P450 by toluene. Int. J. Biochem. 1994; 26: 1333–1340, B. J. Roberts, B. J. Song, and S. E. Shoaf, Induction of CYP2E1 by ethanol is due to protein stabilisation, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 175; B. J. Roberts, B. J. Song, and S. E. Shoaf, Induction of CYP2E1 in liver, kidney, brain and intestine during chronic ethanol administration and withdrowal: Evidence that CYP2E1 possess a rapid phase half-life of 6 hours or less, Biochem. Biophys. Res. Commun., 205, 1064–1071 (1994)
  • Gorski J. C., Wrighton S. A., Jones D. R., Hall S. D. The contribution of cytochrome P450 3A (CYP3A) to the 6-hydroxylation of chlorzoxazone. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October, 23–271994. Vol. 6: 116, Berthou, V. Carriere, D. Ratansavanh, T. Goasduff, F. Morel, J.-C Gautier, A. Guillouzo, and P. Beaune, On the specificity of chlorzoxazone as drug probe of cytochrome P4502E1, ISSX Proceedings, 5th European ISSX Meeting, Tours, France, September 26–29, 1993, Vol. 3, p. 116
  • Dresibach A. W., Fertencz N., Hopkins N. E., Fuentes M. G., Rege A. B., George W. J., Lertora J. J. L. Urinary excretion of 6-OH-chlorzoxazone (CXZ-OH) as an index of cytochrome P4502E 1 activity. Clin. Pharmacol. Ther. 1996; 58: 498–505
  • Girre C., Lucas D., Hispard E., Menez C., Dally S., Menez J.-F. Assessment of cytochrome P450 2E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem. Pharmacol. 1994; 47: 1503–1508
  • Tassaneeyakul W., Veronese M. E., Birkett D. J., Gonzalez F. J., Miners J. O. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol. 1993; 46: 1975–1981, S. P. Carpenter and J. M. Lasker, Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes, Mol. Pharmacol., 49, 260–268 (1996)
  • Gillam E. M. J., Guo Z., Guengerich F. P. Expression of modified human cytochrome P450 2E1 in Echerichia coli: Purification, and spectral and catalytic properties. Arch. Biochem. Biophys. 1994; 312: 59–66, W. Chen, R. M. Peter, K. E. Thumel, and S. D. Nelson, Baculovirus expression and purification of human cytochrome P450 2E1, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 365; J. S. Dong and T. D. Porter, Coexpression of mammalian cytochrome P450 and reductase in Escherichia coli, Arch. Biochem. Biohys., 327, 254–259 (1996); C. L. Crespi, P. W. Penman, F. J. Gonzales, H. V. Gelboin, and R. Langenbach, Cytochrome P450 cDNA expression in human cells: Applications to xenobiotic metabolism and toxicity, ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October 23–27, 1994, Vol. 6, p. 6
  • Stephens E. A., Taylor J. A., Kaplan N., Yang C.-H, Ling Hsieh L., Lucier G. W., Bell D. A. Ethnic variation in the CYP2E1 gene: Polymorphism analysis of 695 Africans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4: 185–192, K. T. Kivistö, A. Linder, G. Friedel, P. Beaune, C. Belloc, H. K. Kroemer, and P. Fritz, Immunohistochemical localization of cytochrome P450 2E1 in human pulmonary carcinoma and normal bronchial tissue, Virchows. Arch., 426, 243–247 (1995)
  • Herbst J., Köster U., Kerssebaum R., Dekant W. Role of P450 2E1 in the metabolism of 1,1,2,2,-tetrafluoro-1-(2,2,2-trifluoroethoxy)ethane. Xenobiotica 1994; 24: 507–516, G. Urban, P. Speerschnaider, and W. Dekant, Metabolism of the chlorofluorocarbon substitute 1,1,-dichloro-2,2,2-trifluoroethane by rat and human liver microsomes: The role of cytochrome P450 2E1, Chem. Res. Toxicol., 7, 170–176 (1994); W. Dekant, M. Assman, and G. Urban, The role of cytochrome P450 2E1 in species-dependent biotransformation of 1,2-dichloro-1,1,2-trifluoroethane in rats and mice, Toxicol. Appl. Pharmacol., 135, 200–207 (1995)
  • Mitra A. K., Thummel K. E., Kalhorn T. F., Kharsch E. D., Unadkat J. D., Slattery J. T. Metabolism of dapsone in human liver by cytochrome P450 2E1 in vivo and in votro. Clin. Pharmacol. Ther. 1995; 58: 556–566, H. J. Gill, M. D. Tingle, and B. K. Park, N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: Implications for inhibition of haematoxicity, Br. J. Clin. Pharmacol., 40, 531–538 (1995); M. D. Coleman, L. E. Rhodes, A. K. Scott, J. L. Verbov, P. S. Friedman, and A. M. Breckenridge, The use of cimetidine to reduce dapsone dependent methaemoglobinaemia in dermatitis herpetiformis patients, Br. J. Clin. Pharmacol., 34, 244–249 (1992). L. E. Rhodes, M. D. Tingle, B. K. Park, P. Chu, J. L. Verbov, and P. S. Friedman, Cimetidine improves the terapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy, Br. J. Dermatol., 132, 257–262 (1995); D. J. Occhipinti, A. Choi, K. Deyo, L. H. Danzinger, and J. H. Fischer, Influence of rifampin and clarithromycin on dapsone disposition and methemoglobin concentrations, Clin. Pharmacol. Ther., 57, 163 (OI-B-2) meeting-abstract (1995)
  • Watkins P. B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171–184, P. B. Watkins, S. A. Murray, L. G. Winkelman, D. M. Heuman, S. A. Wrighton, and P. S. Guzelian, Erythromycin breath test as an assay of glucocorticoidinducible liver cytochromes P450, J. Clin. Invest., 83, 88–697 (1989); H. Yamazaki, S. Hiroki, T. Urano, K. Inuoe, and T. Shimada, Effects of roxithromycin, erythtomycin and troleandomycin in their N-demethylation by rat and human cytochrome P450 enzymes, Xenobiotica, 26, 1143–1153 (1996); K. T. Kivisto, G. Bookjans, M. F. Fromm, E.-U. Griesse, P. Münzel, and H. K. Kroemer, Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue, Brit. J. Clin. Pharmacol., 51, 289–286 (1996)
  • Mäenpää J., Pelkonen O., Cresteil T., Rane A. The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J. Steroid Biochem. Mol. Biol. 1993; 44: 61–17, J. Mäenpää, T. Syngelmä, P. Honkakoski, M. A. Lang, and O. Pelkonen, Comparative studies on coumarin and testosterone metabolism in mouse and human livers: Differential inhibitions by the anti-P450Coh antibody and metyrapone, Biochem. Pharmacol., 42, 1229–1235 (1991)
  • Maurice M., Pichard L., Daujat M., Fabre I., Joyeux H., Domergue J., Maurel P. Effects of imidazole derivatives on cytochrome P450 from hu man hepatocytes in primary culture. FASEB J. 1992; 6: 752–758
  • Waxman D. J., Attisano C., Guengerich F. P., Lapenson D. P. Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P450 enzyme. Arch. Biochem. Biophys. 1988; 263: 424–436, C. Ged, J. M. Rouillon, L. Pichard, J. Combalbert, N. Bressot, P. Bories, H. Michel, P. Beaune, and P. Maurel, The increase in urinary excretion of 6β-hydroxycortisol as a marker of human cytochrome P450IIIA induction, Br. J. Clin. Pharmacol., 28, 373–387 (1989); J. C. Flaishaker, L. K. Pearson, and G. R. Peters, Phenytion causes a rapid increase in 6-beta-hydroxycortisol urinary-excretion in humans: A putative measure of CYP3A induction, J. Pharm. Sci., 84, 292–294 (1995)
  • Ducharme M. P., Warbasse L. H., Edwards D. J. Grapefruit juice affects oral but not iv cyclosporine disposition in man. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October, 23–271994. Vol. 6: 81, D. J. Edwards, F. H. Bellevue, P450 inhibitor in grape fruit juice, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct. 20-Oct 25, Vol. 10, p. 254, 1996; D. J. Edwards and S. M. Bernier, Naringin and naringenin are not the primary CYP3A Inhibitors of grap fruit juice, Life Sci., 59, 1025–1030 (1996)
  • Bailey D. G., Arnold J. M. O., Tran L. T., Abktar J., Spence J. D. Marked effects of both erythromycin and grapefruit juice on felodipine pharmacokinetics. Clin. Pharmacol. Ther. 1994; 55: 165, (PII-48) meeting-abstract, D. G. Bailey, J. M. O. Arnold, J. R. Bend et al., Grapefruit juice-felodipine interaction: Reproducibility and characterization with the extended release drug formulation, Br. J. Clin. Pharmacol., 40, 135–140 (1995); R. E. Benton, P. K. Honig, K. Zamani, L. R. Cantilena, and R. L. Woosley, Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrochardiogram, Clin. Pharmacol. Ther., 59, 383–388 (1996)
  • Pellinen P., Honkakoski P., Stenback F., Niemitz M., Alhava E., Pelkonen O., Lang M. A., Pasanen M. Cocaine N-de-methylation and the metabolism related hepatotoxicity can be prevented by cytochrome P4503A inhibitors. Eur. J. Pharmacol. 1994; 270: 35–43, M. Pasanen, P. Pellinen, F. Stenback, R. O. Juvonen, H. Raunio and O. Pelkonen, The role of CYP enzymes in cocaine-induced liver-damage, Arch. Toxicol., 69, 287–290 (1995)
  • Gorski J. C., Hall S. D., Jones D. R., Vanden Branden M., Wrighton S. A. Regioselective biotransformation of midazolam by members of the human cytochrome P453A (CYP3A) subfamily. Biochem. Pharmacol. 1994; 47: 1643–1653, T. D. Podoll, K. L. Kunze, K. E. Thummel, J. M. Fisher, and W. F. Trager, Evidence supporting mechanism-based inactivation of CYP3A by midazolam, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, p. 154; T.Yokoi, Y. Li, M. Sasaki, R. Kitamura, M. Gunji, M. Katsuki, and T. Kamataki, Metabolic activation of aflatoxin B1 by human fetus-specific cytochrome P450 (CYP3A7) expressed in transgenic mice, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, pp. 9, 214
  • Kupferschmidt H. H. T., Ha H. R., Ziegler W. H. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 1995; 58: 20–28
  • Olkkola K. T., Backman J. T., Neuvonen P. J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 1994; 55: 481–485, S. A. Wrighton and B. J. Ring, Inhibition of CYP3A catalyzed 1′-hydroxy midzolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine, Pharmacol. Res., 11, 921–924 (1994)
  • Honig P., Wortham D., Hull R., Zamani K., Smith J., Cantinela L. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. Clin. Pharmacol. Ther. 1994; 55: 165, (PII-49) meeting-abstract
  • Gomez D. Y., Hebert M., Benet L. Z. The effect of ketoconazole on the intestinal metabolism and bioavaiability of cyclosporine. Clin. Pharmacol. Ther. 1994; 55: 209, (BIII-O-3) meeting-abstract, D. Y. Gomez, V. J. Watcher, S. J. Tomlanovich et al., The effect of ketoconazole on the intestinal metabolism and bioavaiability of cyclosporine, Clin. Pharmacol. Ther., 58, 15–19 (1995)
  • Paine M. F., Kunze K. L., Shen D. D., Lown K. S., Watkins P. B., Thummel K. E. Hydroxylation of midazolam as an indicator of human intestinal CYP3A activity. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, Oct., 23–271994. Vol. 6: 243, C. Wandel, R. Böcker, H. Böhrer, A. Browne, E. Rügheimer, and E. Martin, Midazolam is metabolized by at least 3 different cytochrome P450 enzymes, Br. J. Anaesth., 73, 658–661 (1994); K. E. Thumel and K. L. Kunze, Design and interpretation of kinetic studies in the characterization of cytochrome P450-dependent drug metabolism, in Short Course I, ISSX Meeting, Seattle, WA, August 27-September 1, 1995
  • Olsen A. K., Stentoft K., Tainaka H., Hansen K. T. Ethinylestradiol metabolism by cDNA-expressed human cytochrome P450. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 90, A. Weber, R. Jager, A. Borner, G. Klinger, R. Vollanth, K. Matthey, and A. Balogh, Can grapefruit juice influence ethinylestradiol bioavailability? Contraception, 53, 41–47 (1996)
  • Hoing P. K., Wortham D. C., Zamani K., Conner D. P., Mulin J. C., Cantilena L. R. Terfenadine-ketoconazole interaction, pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–1518, L. L. von Moltke, D. J. Greenblatt, A. X. Duan, J. S. Harmatz, and R. I. Shader, In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction, J. Clin. Pharmacol., 34, 1222–1227 (1994)
  • Terfenadine: Withdrawal from OTC sale. WHO Pharm. Newslett. 1994; 3, Nos. 11/12, Regulatory actions
  • Kerr B. M., Thummel K. T., Wurden C. J., Klain S. M., Kroetz D. L., Gonzalez F. J., Levy R. H. Human liver carbamazepine metabolism, Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol. 1994; 47: 1969–1979
  • Yue Q.-Y., Tomson T., Säwe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 1994; 4: 193–198
  • Walker D., Flinois J.-P., Monkman S. C., Beloc C., Boddy A. V., Cholerton S., Daly A. K., Lind M. J., Pearson A. D. J., Beaune P. H., Idle J. R. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol. 1994; 47: 1157–1163
  • Murray M., Butler A. M., Stupans I. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6β-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. J. Pharmacol. Exp. Ther. 1994; 270: 645–649
  • Lee H. S., Jin C. B., Chong H. S., Yun C. H., Park J. S., Kim D. H. Involvement of P450 3A in the metabolism of 7,8-benzoflavone by human liver microsomes. Xenobiotica 1994; 24: 1053–1062, H. S. Lee, C. B. Jin, J. Park, and D. H. Kim, Modulation of cytochrome P450 activities by 7,8-benzoflavone and its metabolites, Biochem. Mol. Biol. Int., 34, 483–491 (1994)
  • Ring B. J., Parli C. J., George M. C., Wrighton S. A. In vitro metabolism of zatosteron: interspecies comparison and role of CYP 3A. Drug Metab. Dispos 1994; 22: 352–357
  • Relling M. V., Nemec J., Schuetz E. G., Schuetz J. D., Gonzalez F. J., Korzekwa K. R. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450. Mol. Pharmacol. 1994; 45: 352–358
  • May D. G., Porter J., Wilkinson G. R., Branch R. A. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a White population. Clin. Pharmacol. Ther. 1994; 55: 492–500, A. K. Mitra, D. L. Schobor, and D. B. Michell, Dapsone as a probe for microsomal cytochrome P4503A4 and 2E1 in different species, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct. 20-Oct 25, Vol. 10, p. 247, 1996
  • Kumar G. N., Walle T. Paclitaxel (Taxol) 6a-hydroxylation: Role of CYP3A and the effect of other drugs. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October, 23–27, 1994; Vol. 6: 181, G. N. Kumar, U. K. Walle, and T. Walle, Cytochrome P4503A-mediated human liver taxol 6-alpha-hydroxylation, J. Pharmacol. Exp. Ther., 268, 1160–1165 (1994); J. W. Harris, A. Rahman, B.-R. Kim, F. P. Guengerich, and J. Collins, Metabolism of taxol by human hepatic microsomes and human liver slices, ISSX Proceedings, 5th European ISSX Meeting, Tours, France, September 26–29, 1993, Vol. 3, p. 24; J. W. Harris, A. Rahman, B.-R. Kim, F. P. Guengerich, and J. Collins, Metabolism of taxol by human hepatic microsomes and human liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme, Cancer Res., 54, 4026–4035 (1994); T. Cresteil, B. Monsarrat, P. Alvinerie, J. M. Treluyer, I. Vieira, and M. Wright, Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation, Cancer Res., 54, 386–392 (1994); D. Sonnichsen, E. Shuetz, J. Shuetz, A. Pappo, and M. Relling, Variability in human in vitro and in vivo metabolism of paclitaxel, J. Pharmacol. Exp. Ther., 275, 566–575 (1995)
  • Palamanda J. R., Unadkat J. D. Kinetics of cytochrome isoforms involved in the metabolism of trimethoprim in human microsomes. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October, 23–271994. Vol. 6: 241
  • Kharasch E. D., Mautz D., Labroo R. In vitro-in vivo correlations of human opoid metabolism: The role of cytochrome P450 3A4 in alfentanil pharmacokinetics. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October, 23–271994. Vol. 6: 176
  • Crespi C. L., Penman P. W., Gonzales F. J., Gelboin H. V., Galvin M., Langenbach R. Genetic toxicology using human cell lines expressing human P450. Biochem. Soc. Trans. 1993; 21: 1023–1028, C. L. Crespi E. L. Code, B. W. Penman, and D. J. Waxman, An activity-based method for integrating metabolism data from cDNA-expressed cytochrome P450 enzymes to the balance of enzymes in human liver microsomes, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 420
  • Gorski J. C., Hamman M. A., White Y., Wrighton S. A., Hall S. D. Biotransformation of alprazolam by the human cytochrome P450 3A (CYP3A) subfamily. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August27-September, 11995. Vol. 8: 68
  • Vahre A., Klaus M. B., Olkkola T., Neuvonen P. J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics. Clin. Pharmacol. Ther. 1994; 56: 601–607, L. L. von Moltke, D. J. Greenblatt, J. S. Harmatz, S. X. Duan, L. M. Harrel, M. M. Cotreau-Bibbo, G. A. Pritchardt, C. E. Wright, and R. I. Shader, Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole, J. Pharmacol. Exp. Ther., 276, 370–379 (1996); A. Varhe, M. B. Klaus, T. Olkkola, and P. J. Neuvonen, Diltiazem enhances the effects of triazolam by inhibiting its metabolism, Clin. Pharmacol. Ther., 59, 369–375 (1996)
  • Zang Z. I., Fasco M. J., Guengerich F. P., Kaminsky L. S. Warfarin metabolism by human P4501A1 and 1A2-noninvasive probe. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September, 11995, 81, L. S. Kaminski, S. M. F. Demorais, M. B. Faletto, D. A. Dunbar, and J. A. Goldstein, Correlation of human cytochrome P450 substrate specificities with primary structure: Warfarin as a probe, Mol. Pharmacol., 43, 234–239 (1993); J. F. Darbyshire, K. R. Iyer, J. Grogan, K. R. Korzekwa, and W. F. Trager, Selectively deuterated warfarin: Substrate probe for the mechnism of aromatic hydroxylation catalysed by cytochrome P450, Drug Metab. Dispos., 24, 1038–1945 (1996); K. L. Kunze, Prediction and management if metabolism-based drug interactions: In vitro-in vivo correlations, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 4; L. C. Wienkers, K. L. Kunze, and W. F. Trager, The effect of fluconazole on the metabolism of the warfarin enantiomers by human liver microsomes, ISSX Proceedings, 5th North American ISSX Meeting, Bal Harbour, Fl, November 2–6, 1992, Vol. 2, p. 20; K. L. Kunze, L. C. Wienkers, K. E. Thumel, and W. F. Trager, Warfarin-fluconazole I—Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies, Drug Metab. Dispos., 24, 414–421 (1996)
  • Pearce R. E., Rodrigues D., Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 82, L. Prichard, R. Curi-Pedrosa, C. Bonfils, E. Jacqz-Aigrain, J. Domergue, H. Joyeux, J. Cosme, F. P. Guengerich, and P. Maurel, Oxidative-metabolism of lansoprazole by human liver cytochromes P450, Mol. Pharmacol., 47, 410–418 (1995)
  • Sadeque A. J. M., Korzekwa K. R., Gonzalez F. J., Rettie A. E. Identification of human liver P450 enzymes responsible for the formation of 4-ene valproic acid. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 187
  • Jang G. R., Benet L. Z. Evidence for human liver microsomal cytochrome P4503A mediated metabolism of mefipristone (RU486). ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August27-September, 11995. Vol. 8: 92, G. R. Jang, S. A. Wrighton, and L. Z. Benet, Identificaton of CYP3A4 as the principal enzyme catalyzine mifepristone (RU 486) oxidation in human liver microsomes, Biochem. Pharnutcol, 52, 753–762 (1996)
  • Shepard D. R., Krecic M. E., Mays D. C., Boyd R. T., Lasker J., Raucy J., Gerber N. Metabolism of phenytion by human and rat liver microsomes, cytochrome P450s 2C8 and 2C9 expressed in cos-1 cells, and purified P450s 2C8 and 2C9. ISSX Proceedings, 5th European ISSX Meeting, ToursFrance, September, 26–291993. Vol. 3: 44, D. R. Shepard, M. E. Krecic, T.-H. Chang, J. Collins, and N. Gerber, Metabolism of phenytion by human cytochrome P450s 2C9 and 2C18 expressed in yeast, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, p. 95; M. E. Krecic, D. R. Shepard, T.-H. Chang, J. Collins, and N. Gerber, Stereoselective metabolism of phenytion by hepatic microsomes and human 2C9 and 2C18 expressed in yeast, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, p. 370
  • Spracklin D. K., Thummel K. E., Kharasch E. D. Reductive halothane metabolism in humans. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August27-September, 11995. Vol. 8: 98, D. K. Spracklin, D. C. Hankins, K. E. Thummel, and E. D. Kharasch, Human oxidation halothane metabolism in vitro is catalyzed by 2A6 and 2E1, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, October 20–25, 1996, Vol. 10, p. 377
  • Chen W. C., Nelson S. D. Oxidation of acetaminophen to its toxic quinone imine and non-toxic catechol metbolites by purified human cytochrome P450 2E1. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August27-September, 11995. Vol. 8: 224, C. A. Lee, K. E. Thumel, K. R. Korzekwa, S. D. Nelson, and J. T. Slattery, Contribution of human P450 2E1, 1A2, and 3A4 to the bioactivation of acetaminophen, ISSX Proceedings, 5th North American ISSX Meeting, Bal Harbour, FL, November 2–6, 1992, Vol. 2, p. 17; W. C. Chen, K. E. Thumel, S. D. Nelson, and J. T. Slattery, Pharmacokinetic model of the effect of CYP2E1 induction by protein stabilization on substrate clearance, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 329; W. C. Chen, R. M. Peter, R. L. Haining, A. E. Rettie, and S. D. Nelson, Selective oxidation of acetaminophen by major human cytochrome P450 isozymes, ISSX Proceedings, 7th North American ISSX Meeting, San Diego CA, USA, October 20–25, 1996, Vol. 10, p. 374; R. H. Levy, Cytochrome P450 isozymes and antiepileptic drug interactions, Epilepsia, 36 (Suppl. 5, 8–13 (1995)
  • Botsch S., Gautier J.-C., Beaune P., Eichelbaum M., Kroemer H. K. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: Molecular base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol. 1993; 43: 120–126
  • Imaoka S., Enomoto K., Oda Y., Asada A., Fujimori M., Shimada T., Fujita S., Guengerich F. P., Funae Y. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: Comparison of those with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther. 1990; 255: 1385–1391
  • Berson A., Wolf C., Chachaty C., Fisch C., Fau D., Eugene D., Loeper J., Gauthier J.-C., Beaune P., Pompon D. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and IA subfamilies. J. Pharmacol. Exp. Ther. 1993; 265: 366–372
  • Salcedo J. A., Yasuda S. U., Murphy M. P., Woosley R. L., Flockhart D. A. Stereoselective inhibition of CYP2D6 by chlorpheniramine. Clin. Pharmacol. Ther. 1995; 57: 149, (PI-59) meeting-abstract, T. Hiroi, N. Ohishi, S. Imaoka, Y. Yabusaki, H. Fukui, and Y. Funae, Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic-activity of rat and human P450 2D forms, J. Pharmacol. Exp. Ther., 272, 939–944 (1995)
  • Chang T. K. H., Weber G. F., Crespi C. L., Waxman D. J. Differential activation of cyclophosphamide and iphosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993; 53: 5629–5637, T. K. H. Chang, J. A. Goldstein, and D. J. Waxman, Cyclophosphamide 4-hydroxylation and ifosfamide 4-hydroxylation catalyzed by recombinant human CYP2C9 and CYP2C18 expressed in yeast, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 361; D. J. Waxman, Role of human P450 enzymes in anti-cancer drug activation: the example of cyclophosphamide, in: Metabolism in cancer chemotherapy, Short Course C, 7th North American ISSX Meeting, San Diego, USA, Oct. 20–OCt 24, 1996; F. Bohnenstengel, U. Hofmann, M. Eichelbaum and H. K. Kroemer, Characterization of the cytochrome P450 involved in side chain oxidation of cyclophosphamide in humansm, Eur. J. Clin. Pharmacol., 51, 297–301 (1996)
  • De Montelano O., Chan W. K., Tack S. E., Kaikaus R. M., Bass N. M., Peterson J. A. Mechanism-based probes of the topology and function of fatty acid hydroxylases. FASEB J. 1992; 6: 695–699
  • Ha H. R., Wyss P. A., Stieger B., Meier P. J., Meyer U. A., Follath F. Amiodarone metabolism in human liver microsomes. FASEB J. 1992; 6: A1845, meeting-abstract
  • Crewe H. K., Lennard M. S., Tucker G. T., Woods F. R., Haddock R. E. The effect of paroxetine and other specific 5-HT re-uptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Proceedings of the BPS. July, 10–121991, Br. J. Clin. Pharmacol., 32, 658P-659P, meeting-abstract (1991); H. K. Crewe, M. S. Lennard, G. T. Tucker, F. R. Woods, and R. E. Haddock, The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes, Br. J. Clin. Pharmacol., 34, 262–265 (1992); J.-P. Wang and J. D. Unadkat, Human P450 isoforms involved in the formation of the active metabolites of (R)- and (S)-fluoxetine, ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27-September 1, 1995, Vol. 8, p. 385; L. L. van Moltke, D. J. Greenbalatt, M. H. Court, S. X. Duen, J. S. Harmatz, and R. I. Shader, Inhibition of alprazolam and desipramine hydoxylation in vitro by paroxetine and fluvoxamine, Clin. Pharmacol. Ther., 57, 221 (O111–33) meeting-abstract (1995); Regulatory actions, Fluvoxamine: Increased theophylline levels, WHO Pharm. Newslett., Nos. 11/12, 1994, p. 5; K. Brosen, E. Skjelbo, B. B. Rasmussen, H. E. Poulsen, and S. Loft, Fluvoxamine is a potent inhibitor of cytochrome P450 1A2, Biochem. Pharmacol., 45, 1211–1214 (1993); Jeppessen, L. F. Gram, K. Vistisen, S. Loft, H. E. Poulsen, and K. Brosen, Dose dpendent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine, and paroxetine, Eur. J. Clin. Pharmacol., 51, 73–78 (1996); B. A. Hamelin, J. Turgeon, F. Vallee, P.-M. Belanger, F. Paquet, and M. LeBell, The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin, Clin. Pharmacol. Ther., 60 512–521 (1996)
  • Feifel N., Kucher K., Schmidt E., Antonin K. H., Bieck P. R. (1991) Influence of quinidine on pharmacokinetics and metabolism of the MAO-A inhibitor brofaromine: Role of the debrisoquine-sparteine cytochrome P450. Abstract 32nd Spring Meeting, Mainz, Deutsch, March, 12–151991. 343: 25R7, Gesselschaft für Pharmakologie and Toxikologie, Naunyn Schmiedebergs Arch. Pharmacol., Suppl.
  • Ferrari S., Leeman T., Dayer P. The role of lipophilicity in the inhibition of polymorphic cytochrome P450 D6 oxidation by beta-blocking agents in vitro. Life Sci. 1991; 48: 2259–2265
  • Kerlan V., Dreano Y., Bercovici J. P., Beaune P. H., Floch H. H., Berthou F. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem. Pharmacol. 1992; 44: 1745–1756
  • Skjelbo E., Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 1992; 34: 256–261, A. Lemoine, J. C. Gautier, D. Azoulay, L. Kiffel, C. Beloc, F. P. Guengerich, R. Maurel, P. Beaune, and J. P. Leroux, Major pathway of imipramine metabolism is catalyzed by cytochromes P450 1A2 and P450 3A4 in human liver, Mol. Pharmacol., 43, 827–832 (1992); O. O. Bolaji, R. T. Courts, and G. B. Baker, Metabolism of trimipramine in vitro by human CYP2D6 isoenzyme, Res. Commun. Chem. Pathol. Pharmacol., 82, 111–120 (1993); P. Su, R. T. Coutts, G. B. Baker, and M. Dansehtalab, Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line, Xenobiotica, 23, 1289–1298 (1993); L. L. von Moltke, D. J. Greenblatt, M. M. Cotreau-Bibbo, S. X. Duan, J. S. Harmatz, and R. I. Shader, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake inhibitor antidepressants, and by quinidine and ketoconazole: A novel system to predict drug interactions in vivo, J. Pharmacol. Exp. Ther., 268, 1278–1283 (1994); L. L. von Moltke, J. S. Harmatz, G. Aberg, and R. I. Shader, Differential inhibition of desipramine hydroxylation in vitro by the enantiomers of fluoxetine, Clin. Pharmacol. Ther., 57, 205 (PIII-44) meeting-abstract (1995); L. J. Albers, C. Reist, D. Helmeste, R. Vu, and S. W. Tang, Paroxetine shifts imipramine metabolism, Psychiatry Res., 59, 189–196 (1996)
  • Eichelbaum M. How realiable are in vitro approaches for the prediction of human in vivo drug metabolism. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August27-September, 11995. Vol. 8: 3, G. Engel, U. Hofman, H. Heideman, J. Cosme, and M. Eichelbaum, Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrom P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxyantipyrine, and 4-norantipyrine, Clin. Pharmacol. Ther., 59, 613–623 (1996)
  • Agundez J. A. G., Martinez C., Benitez J. Metabolism of aminopyrine and derivatives in man: In vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica 1995; 25: 417–427
  • Blake B. L., Rose R. L., Mailman R. B., Levi P. E., Hodgson E. Metabolism of thioridazine by microsomal monooxygenases: Relative role of P450 and flavin-containing monooxygenase. Xenobiotica 1995; 25: 377–393
  • Zhou-Pan X.-R., Seree E., Zhou X.-J., Placidi M., Maurel P., Barra Y., Rahmani R. Involvement of human liver cytochrome P4503A in vinblastine metabolism: Drug interactions. Cancer Res. 1993; 53: 5121–5126, M. V. Relling, Does interindividual variability in drug metabolism translate into important clinical pharmacokinetic and pharmacodinamic differences, in: Metabolism in cancer chemotherapy, Short Cource C, 7th North American ISSX Meeting, San Diego, USA, October 20–24, 1996
  • Nakasa H., Komiya M., Ohmori S., Rikihisa T., Kiuchi M. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol. Pharmacol. 1993; 44: 216–221
  • Vyas K. P., Kari P. H., Pitzenberger S. P., Wang R. W., Lu A. Y. H. Identification of 3′,5′-dihydro-3′,5′-diol-δ4-lovastatin as a new cytochrome P450 3-acetalyzed metabolite of lovastatin in rat and human liver microsomes. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, AZ, October, 17–211993. Vol. 4: 35
  • Waxman D. J., Chang T. K. H., Chen G. Interactions of anticancer drugs with cytochromes P450 and glutathione S-transferases: Drug activation and drug resistance mechanisms. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, AZ, October, 17–211993. Vol. 4: 2
  • Labroo R. B., Karasch E. D. Human liver microsomal alfetanil metabism: GC/MS assay and predominant catalytic role of P450 3A3/4. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, AZ, October, 17–211993. Vol. 4: 144
  • Mitra A. K., Kalhorn T. F., Thummel K. E., Unadkat J. D., Slattery J. T. Metabolism of arylamines by human liver microsomal cytochrome P-450s. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, AZ, October, 17–211993. Vol. 4: 148
  • Andersson P., Jönsson G. Metabolism of budesonide in human liver is catalysed by cytochrome P450 3A isoenzymes. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, AZ, October, 17–211993. Vol. 4: 236, G. Jönsson, A. Aström, and P. Anderson, Budesonide is metabolised by cytochrome P450 3A (CYP3A) enzymes in human liver, Drug Metab. Disposition, 23, 137–142 (1995)
  • Berthou F., Dreano Y., Belloc C., Kangas L., Beaune P. Involvement of cytochrome P450 3A in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol. 1994; 47: 1883–1895
  • Simon I., Berthou F., Riche C., Beaune P., Ratanasavanh D. Both cytochromes P450 IA and 3A4 are involved in the N-demethylation of tamoxifen. ISSX Proceedings, 5th European ISSX Meeting, Tours, France, September, 26–291993. Vol. 3: 44, M. L. Williams, M. S. Lennard, I. J. Martin, and G. T. Tucker, Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver-microsomes, Carcinogenesis, 15, 2733–2738 (1994); Regulatory actions, Tamoxifen-genotoxicity, WHO Pharm. Newslett., No. 1, 1995, p. 4; S. S. Dehal, C. Mani, and D. Kupfer, Covalent binding of tamoxifen and its metabolites: 4-Hydroxytamoxifen a proximate species to the reactive intermediate in rats and humans, ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, October 23–27, 1994, Vol. 6, p. 160
  • Gillet G., Pichard L., Filali-Ansary A., Thenot J.-P, Maurel P. Identification of the major cytochromes P450 involved in the formation of plasma metabolite of alpidem in man. ISSX Proceedings, 5th European ISSX Meeting, ToursFrance, September, 26–291993. Vol. 3: 47
  • Bauer E., Gou Z. Y., Ueng Y. F., Bell L. C., Zeldon D., Guengerich F. P. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 1995; 8: 136–142
  • Daikh B. E., Lasker J. M., Raucy J. L., Koop D. R. Regioselective and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther. 1994; 271: 1427–1433
  • Yu E., Kovaleva I. E., El'darov M. A., Luzikov V. N. Heterologous expression of functionally active human cytochromes P450. I: Synthesis of cytochrome P450 2D6 transformed by Saccharomyces cerevisiae cells. Mol. Biol. 1993; 27: 677–680, E. Yu, I. E. Kovaleva, and V. N. Luzikov, Heterologous expression of functionally active human cytochromes P450. II: Modeling of xenobiotic metabolism by Saccharomyces cerevisiae cells expressing cytochrome P450IIIA4, Mol. Biol., 28, 63–66 (1994); E. Y. Krynetskii, I. E. Kovaleva, and V. N. Luzikov, Heterologous expression of functionally active human cytochromes P450—cytochrome P450IIIA catalyzes conversion of the anabolic-steroid hormolne methandrostenolone, Biochemistry(Moscow), 59, 203–206 (1994); A. Schneider, W. A. Schmalix, V. Siruguri, E. M. deGroene, G. J. Horbach, B. Kleingeist, D. Lang, R. Bocker, and P. Buane et al., Stabke expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells, Arch. Biochem. Biophys., 332, 295–304 (1996)
  • Deuscher R. J., Elfarra A. A. Human liver-microsomes are efficient catalysts of 1,3-butadiene oxidation: Evidence for major roles by cytochromes P450 2A6 and 2E1. Arch. Biochem. Biophys. 1994; 311: 342–349
  • Wienkers L. C., Steenwyk R. C., Sanders R. C., Pearson P. G. CYP3A4 and 5α-reductase mediated clearance of tirilazad in human liver. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 78, L. C. Wienkers, R. C. Steenwik, P. E. Sanders, and P. G. Pearson, Biotransformation of tirilazad in human. 1. Cytochrome P4503A-mediated hydroxylation of tirilazad mesylate in human liver microsomes, J. Pharmacol. Exp. Ther., 277, 982–990 (1996)
  • Russell A. L., Herron W. J., Rush W. R., Graham D. J. The involvement of cytochrome P450 3A (CPY3A) in the metabolism of ranolazine in human liver. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 89
  • Kamimura H., Oishi S., Ochiai H., Watanabe T., Higuchi S., Hall M., Wood S. G., Chasseaud L. F. Idnetification of P450 isozymes involved in metabolism of the α1-adrenoceptor blocker tamsulosin in human liver microsomes. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 93
  • Sanwald P., David M., Dow J. Role of CYP2D6 in the metabolism of the 5-HT3 antagonists, tropisetron, ondansetron and dolasetron. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 96, P. Sanwald, M. David, and J. Dow, Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron: Comparison with other indole-containing 5-HT3 anatagonists, Drug Metab. Dispos., 24, 602–609 (1996)
  • Smith B. J., Zupan L. A., Riley Pamela. Interactions of azimilide with human hepatic microsomal cytochromes P450 and its metabolism by the P4503A subfamily. ISSX Proceedings, 4th Inter-national ISSX Meeting, Seattle, WA, August, 27-September 11995. Vol. 8: 97
  • Wong B. K., Bruhin P. J., Chiba M., Wang R., Lin J. H. Metabolism of dorzolamide by human liver microsomes and liver slices. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August27-September, 11995. Vol. 8: 140
  • Winter H. R., Unadkat J. D. Human liver microsomal metabolism of sulfadiazine to its toxic hydroxylamine metabolite. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August27-September, 11995. Vol. 8: 236, A. C. Cribb, S. P. Spielberg, and G. P. Griffin, N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the P450 2C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes, Drug Metab. Dispos, 23, 406–414 (1995); H. J. Gill, J. L. Magos, S. Madden, M. Pirmohamed, and K. Park, The effectofo fulconazole and ketoonazole on the metabolimos sulphamethazole, Br. J. Clin. Pharmacol., 42, 347–353 (1996)
  • Weaver R. J., Dickins M., Waller S. J., Chambers J. H., Morley T. J., Burke M. D. Proguanil metabolism in hepatic microsomes and isolated hepatocytes from animals and man, and the effect of atavaquone and CYP inhibitors. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August27-September, 11995. Vol. 8: 295
  • Frame L. T., Si Y., Zelinski W. L., Crespi C. L., Leakey J. E. A. Use of human lymphoblastoid cells expressing human cytochrome P450s or human UDP-glucuronosyltransferases for mechanistic studies of human drug metabolism. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, August 27- September, 11995. Vol. 8: 372
  • Bloomer J. C., Baldwin S. J., Smith G. J., Ayrton A. D., Clarke S. E., Chenery R. J. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br. J. Clin. Pharmacol. 1994; 37: 557–567
  • Raucy J. L., Kraner J. C., Lieber C. S., Lasker J. M. Evidence that human P4502C9 is a low KmN-nitrosodimethylamine (NDMA) demethylase. J. Cell Biol. 1988; 107: 195a
  • Oda Y., Furuichi K., Tanaka K., Hiroi T., Imaoka S., Asada A., Fujimori M., Funae Y. Metabolism of a new local-anesthetic, ropivacaine, by human hepatic cytochrome P450. Anaesthesiology 1995; 82: 214–220, G. Ekstrom, and U. B. Gunnarsson, Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes, Drug Metab. Dispos., 24, 955–961 (1996)
  • Adedoyin A., Mauro K., Frye R., Porter J., Branch R. A. Selective modulation of specific metabolizing activities by chloroquine. Clin. Pharmacol. Ther. 1995; 57: 150, (PI-60) meeting-abstract C. M. Masimirembwa, J. A. Hasler, and I. Johansson, Inhibitory efects of antiparasitic drugs on cytochrome P4502 D6, Eur. J. Clin. Pharmacol., 48, 35–38 (1995)
  • Maurel P. Use of human hepatocytes to characterize the metabolism of drugs (lecture). Short Course I, ISSX Meeting, Seattle, WA, August 27-September, 11995, A. Lampen, U. Christmas, A. Bader, I. Hackbarth, and K.-F. Sewing, Drug interactions and interindividual variability of cyclosporin metabolism, Pharmacology, 52, 159–168 (1996)
  • Ullrich V., Nüsing R. Thromboxane synthase, from isolation to function. Stroke 1990; 21(Suppl. IV)134–138, R. Nusing, R. Lesch, and V. Ullrich, Immunohistochemical localization of thromboxane synthase in human tissue, Eicosanoids, 3, 53–58 (1990); R. Niissing, M. P. Wemet, and V. Ullrich, Production and characterization of polyclonal and monoclonal antibodies against human thromboxan synthase, Blood, 76, 80–85 (1990); T. Tanabe, C. Yokoyama, A. Miyata, H. Ihara, T. Kosaka, K. Suzuki, Y. Nishikawa, T. Yoshimoto, S. Yamamoto, R. Nüsing, and V. Ullrich, Molecular cloning and expression of human thromboxane synthase, J. Lipid Med., 6, 139–144 (1993); C. Yokoyama, A. Miyata, K. Suzuki, Y. Nishikawa, T. Yoshimoto, S. Yamamoto; R. Nüsing, V. Ullrich, and T. Tanabe, Expression of human thromboxane synthase using a baculovirus system, FEBS Lett., 318, 91–94 (1993)
  • Hecker M., Ullrich V. On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J. Biol. Chem. 1989; 264: 141–150, V. Ullrich and T. Tanabe, Prostacyclin and thromboxane synthases, J. Lipid Med., 12, 243–255 (1995); V. Ullrich and R. Brugger, Prostacyclin and thromboxane cynthase: New aspects of hemethiolate catalysis, Angew. Chem., 33, 1911–1919 (1994); V. Ullrich and H. H. Ruf, Heme proteins in prostaglandin biosynthesis, in Metaloporphyrins in Catalytic Oxidations (R. A. Sheldon, ed.), Marcel Dekker, New York, 1994, pp. 157–192
  • Ihara H., Yokoyama C., Miyata A., Kosaka T., Nüsing R., Ullrich V., Tanabe T. Induction of thromboxane synthase and prostaglandin endoperoxide synthase mRNA in human erythroleukemia cells by phorbol ester. FEBS Lett. 1991; 306: 161–164, M. Hecker and V. Ullrich, Studies on the interaction minoxidil with prostacyclin synthase in vitro, Biochem. Pharmacol., 37, 3363–3365 (1988); A. Miyata, S. Nara C. Yokoyama, H. Inoue, V. Ullrich, and T. Tanabe, Molecular cloning and expression of human prostacyclin synthase, Biochem. Biophys. Res. Commun., 200, 1728–1734 (1994)
  • Kagawa N., Waterman M. R. Regulation of steroidogenic enzymes. Cytochrome P450-Structure, Mechanism and Biochemistry, 2nd ed., P. R. Ortiz de Montellano. Plenum Press, New York 1995; 419–442
  • Hanukoglu I. Steroidogenic enzymes: Structure, function, and role in regulation of steroid hormone biosynthesis. J. Steroid Biochem. Mol. Biol. 1992; 43: 779–804
  • Hartmann R. W. Selective inhibition of steroidogenic P450 enzymes: Current status and future perspectives. Eur. J. Pharm. Sci. 1994; 2: 15–16, D. F. Burke, C. A. Laughton, C. F. Snook, and S. Neidle, Active site conformation of 17(3-pyridyl)androsta-5,6-dien-3β-ol, a potent inhibitor of the P450 enzyme C17a-hydroxylase/C17–20 lyase, Bioorg. Med. Chem. Lett., 5, 1125–1130 (1995)
  • Vanden Bossche H. Inhibitors of P450 dependent steroid biosynthesis: From research to medical treatment. J. Steroid Biochem. Mol. Biol. 1992; 43: 1003–1021, H. Vanden Bossche, R. DeCoster, and W. K. Amery, Pharmacology and clinical uses of ketoconazole, in Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action (B. J. A. Fun and AS. E Wakeling, eds.), Bailliere Tindall, London, 1986, p. 288
  • Boidin M. P., Stuurnman A., Erdman W. Inhibition of steroidogenesis by cimetidine in man: A double-blind prospective study. Scand. J. Gastroenterol. 1988; 23: 41–45, C. J. Kenyon, R. Fraser, G. G. Birnie, J. M. C. Connell, and A. F. Lever, Dose related in vitro effects of ranitidine and cimetidine on basal and ACTH stimulated steroidogenesis, Gut, 27, 1143–1145 (1986)
  • Galbreith R. A., Michnowitz J. J. The effect of cimetidine on oxidative metabolism of estradiol. N. Engl. J. Med. 1989; 321: 269–274
  • Rodriguez L., Jick H. Risk of gynecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. Br. Med. J. 1994; 308: 503–506
  • White P. C., Pascoe L., Curnow K. M., Tannin G., Rösier A. Molecular biology of 11β-hydroxylase and 11β-hydroxysteroid dehydrogenase enzymes. J. Steroid Biochem. Mol. Biol. 1992; 43: 827–835
  • Rendic S. Metabolism of testosterone. 10th Cologne Workshop on Dope Analysis, 7th to 12th June, Proceedings. SPORT and BUCH Strauss, Köln 1993; 27–46, S. Rendic, Biochemistry of drug metabolism studies: Metabolism of testosterone and T/E ratio, Acta. Pharm., 44, 215–227 (1994)
  • Sonino N. The use of ketoconazole as an inhibitor of steroid production. N. Engl. J. Med. 1987; 317: 812–818
  • Loose D. S., Kan P. B., Hirst M. A., Marcus R. A., Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P-450-dependent enzymes. J. Clin. Invest. 1983; 71: 1495–1499
  • Weber M. M., Lang J., Abedinpour F., Zeilberger K., Adelmann B., Engelhard D. Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis. Clin. Invest. 1993; 71: 933–938
  • Dowie L. J., Smith J. E., MacGilchrist A. J., Fraser R., Honour J. W., Reid J. L., Kenyon C. J. In vivo and in vitro studies of the site of inhibitory action of omeprazole on adrenocortical steroidogenesis. Eur. J. Clin. Pharmacol. 1988; 35: 625–629
  • Swinney D. C., Mak A. Y. Androgen formation by cytochrome-P450 Cyp17—solvent isotope effect and pL studies suggest a role for protons in the regulation of oxene versus peroxide chemistry. Biochemistry 1994; 33: 2185–2190
  • Hall P. F. Cytochrome P-450 C21scc: One enzyme with two actions: Hydroxylase and lyase. J. Steroid Biochem. Mol. Biol 1991; 40: 527–532, U. M. Zanger, N. Kagawa, J. Lund, and M. R. Waterman, Distinct biochemical mechanisms for cAMP-dependent transcription of CYP17 and CYP21, FASEB J., 6, 719–723 (1992)
  • Hosaka M., Oshima H., Troen P. Studies of the human testis. XIV: Properties of C17-C20 lyase. Acta Endocrinol. 1980; 94: 389–396
  • Simpson E. R., Mahendroo M. S., Means G. D., Kilgore M. W., Hinshelwood M. M., Graham-Lorence S., Amarneh B., Ito Y., Fisher C. R., Michael M. D., Mendelson C. R., Bulun S. E. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. 1994; 15: 342–355, M. Dowsett, Aromatase inhibition: Basic concepts, and pharmacodynamics of formestane, Ann. Oncol., 5, S3–S5 (1994); K. Toda, S. Nomoto, and S. Shizuta, Identification and characterization of transcriptional regulatory elements of the human aromatase cytochrome P450 gene (CYP19), J. Steroid Biochem. Mol. Biol., 56, 151–159 (1996); E. D. Lephart, A review of brain aromatase cytochrome P450, Brain Res. Rev., 22, 1–26 (1996)
  • Bicikova M., Hampl R., Hill M., Starka L. Inhibition of steroid 17α-hydroxylase and C 17,20-lyase in the human testis by epitestosterone. J. Steroid Biochem. Mol. Biol. 1993; 46: 515–1518
  • Howden C. W., Kenyon C. J., Beastall G. H., Reid J. L. Inhibition by omeprazole of adrenocorticol response to ACTH: Clinical studies and experiments on bovine adrenal cortex in vitro. Clin. Sci. 1986; 70: 99–102
  • Pont A., Williams P. L., Loose D. S., Feldman D., Reitz R. E., Bochra C., Steven D. A. Ketoconazole blocks adrenal steroid synthesis, Ann. Intern. Med. 1982; 97: 370–372
  • Trzaskos J. M. Oxylanosterols as modifiers of cholesterol biosynthesis. Progr. Lipid. Res. 1995; 34: 99–116
  • Bogaards J. J. P., Omen B. V., Wolf C. R., Van Bladeren P. J. Human cytochrome P450 enzyme selectivities in the oxidation of chlorinated benzenes. Toxicol. Appl. Pharamcol. 1995; 132: 44–52
  • Donato M. T., Castell J. V., Gómez-Lechón M. J. Effects of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab. Dispos 1995; 23: 553–558
  • Khalil M. W., Strutt B., Vachon D., Killinger D. W. Effect of dexamethasone and cytochrome P450 inhibitors on the formation of 7α-hydroxydehydroepiandrosterone by human adipose stromal cells. J. Steroid Biochem. Mol. Biol. 1994; 48: 545–552
  • Murray G. J., Prirchad S., Melvin W. T., Burke M. D. Cytochrome P450 CYP3A5 in the human anterior pituitary gland. FEBS Lett. 1995; 364: 79–82
  • Abolfathi Z., Pakdel H., Beaune P., Turgeon J. CYP1A2 is the major enzyme involved in the N-oxidation of mexiletine (MEX) in man. Clin. Pharmacol. Ther. 1995; 57: 221, (OIII-A33) meeting-abstract
  • Scmider J., Greenblat D. J., van Moltke L. L., Shader R. I. N-demethylation of amitriptyline in vitro: Role of CYP3A isoforms. Clin. Pharmacol. Ther. 1995; 57: 193, (OII-A-2) meeting-abstract, M. L. Dahl, C. Nordin, and L. Bertilsson, Enantioselective hydroxylation of nortryptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline, Ther. Drug. Monit., 13, 189–194 (1991); B. Pfandl, K. Morike, D. Winne, W. Schareck, and U. Breyer-Pfaff, Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine and ketoconazole, Xenobiotica, 22, 721–730 (1992); U. Breyer-Pfaff, B. Pfandl, K. Nill, E. Nusser, C. Monney, M. Jonzier-Perey, D. Beatting, and P. Baumann, Enantioselective amitriptyline metabolism in patients phenotypes for two cytochrome P450 isoenzymes, Clin. Pharmacol. Ther., 52, 350–358 (1992)
  • Lee Y. S., Reidenberg M. M. Grapefruit juice inhibits 11-β hydroxysteroid dehydrogenase (11-β OHSD). Clin. Pharmacol. Ther. 1995; 57: 173, (PII-39) meeting-abstract
  • Brannan M. D., Affrime M. B., Radwanski D. E., Cayem M. N., Banfield C. Effects of various cytochrome P450 inhibitors on the metabolism of loratadine. Clin. Pharmacol. Ther. 1995; 57: 193, (OIIA-4) meeting-abstract, N. Yumibe, K. Huie, K.-J. Chen, M. Snow, R. P. Clement, and M. N. Cayen, Identification of human liver cytochromes P450 enzymes that metabolise the nonsedating antihistamine loratadine, Biochem. Pharmacol., 51, 165–172 (1996)
  • Jähnchen E., Buschmann M., Trenk D. Pharmacokinetics of the class I antiarhythmic drug diprafenone in poor metabolizers of sparteine/debrisoquine. Clin. Pharmacol. Ther. 1995; 57: 151, (PI-67) meeting-abstract
  • Kimonen T., Juvonen R. O., Alhava E., Pasanen M. The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br. J. Pharmacol. 1995; 114: 832–836, T. Kimonen, M. Pasanen, J. Gynther, A. Poso, T. Järvinen, E. Alhava, and R. O. Juvonen, Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP2A5 and human CYP2A6, Br. J. Pharmacol., 114, 832–836 (1995)
  • Richardson T. H., Jung F., Griffin K. J., Wester M., Raucy J. L., Johnson E. F. Expression and characterization of human cytochrome P4502C enzymes in E. coli: Identification of P4502C19 as a progesterone 21-hydroxylase. FASEB J. 1995; 9: A1489, meeting-abstract
  • Jaeger W., Benet L. Z., Bornheim L. M. Inhibition of cyclosporine and tetrahydrocannabidiol by cannabidiol in mouse and human microsomes. Xenobiotica 1996; 26: 275–284
  • Lake B. G., Charzat C., Tredger J. M., Renwick A. B., Beamand J. A., Price R. J. Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices. Xenobiotica 1996; 26: 297–306
  • Hakkola J., Pasanen M., Hukkanen J., Pelkonen O., Mäenpää J., Edwards R. J., Boobis A. R., Raunio H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. 1996; 51: 403–411
  • Strömsted M., Rozman D., Waterman M. R. The ubiquitously expressed human CYP51 encodes lanosterol 14α-demethylasse, a cytochrome P450 whose expression is regulated by oxysterols. Arch. Biochem. Biophys. 1996; 329: 73–81
  • Miners J. O., Coulter S., Tukey R. H., Veronese M.-E., Birkett D. J. Cytochrome P450 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem. Pharmacol. 1996; 51: 1003–1008, M. A. Hamman, G. A. Thompson, and S. D. Hall, Regioselective and Stereoselective biotransformation of ibuprofen by the human cytochrome 450P2C subfamily, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, October 20–25, 1996, Vol. 10, p. 353
  • de Groene A. M., Hassing I. G. A. M., Blom M. J., Seinen W., Fink-Gremmels J., Horbach G. J. Development of human cytochrome P450-expressing cell lines: Application in mutagenicity testing of ochratoxin A. Cancer Res. 1996; 56: 299–304
  • Kumar G. N., Rodrigues A. D., Buko A. M., Denissen J. F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 423–431
  • Ebner T., Meese C. O., Eichelbaum M. Mechanism of cytochrome P450-catalysed sparteine metabolism in humans. Mol. Pharmacol. 1995; 48: 1078–1086
  • Kamataki T., Hashimoto H., Shimoji M., Itoh S., Nakayama K., Hattori K., Yokoi T., Katsuki M., Aizawa S. Expression of CYP3A7, a human fetus-specific cytochrome P450, in cultured cells and in the hepatocytes of p53-knockout mice. Toxicol. Lett. 1995; 82/83: 879–882
  • Ahmed S., Smith J. H., Nicholls P. J., Whomsley R., Cariuk P. Synthesis and biological evaluation of imidazole based compounds as cytochrome P450 inhibitors. Drug Design Discov. 1995; 13: 27–41
  • Gross A. S., Philips A. C., Rieutord A., Shenfield G. M. The influence of sparteine debrisoquine genetic polylorphism on disposition of desfenfluramine. Br. J. Clin. Pharmacol. 1996; 41: 311–317
  • Christians U., Schmidt G., Bader A., Lampen A., Schottman R., Linck A., Sewing K. F. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br. J. Clin. Pharmacol. 1996; 41: 187–190, A. Lampen, U. Christians, F. P. Guengerich, P. B. Watkins, J. C. Kolars, A. Bader, A. K. Gonschoir, H. Dralle, I. Hackbarth, and K. F. Sewing, Metabolism of immunosupressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability, Drub. Metabol. Dispos, 23, 1315–1324 (1996)
  • Nunoya K. I., Yokoi T., Kimura K., Kodama T., Funayama M., Inuoe K., Nagashima K., Funae Y., Shimada N., Kamataki T. (+)-cis-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one hydroxhloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 768–774
  • Smith T. J., Guo Z. Y., Guengerich F. P., Yung C. S. Metabolism of 4-methylnitrosamino)-1(3-pyridyl)1-butanone (NNK) by hunmman cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. Carcinogenesis 1996; 17: 809–813
  • Chiba M., Hensleigh M., Balani J. A., Lin J. H. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drub Metab. Dispos 1996; 24: 307–314
  • Iribarne C., Berthou F., Baird S., Dreano Y., Picart D., Bail J. P., Beaune P., Menez J. F. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 1996; 9: 365–373
  • Ketter T., Flochart D. A., Post R. M., Denicoff K., Pazaglia P. J., Marangell L. B., George M. S., Callahan A. M. The emerging role of cytochrome P450 3A in psychopharmacology. J. Clin. Psychopharmacol. 1995; 15: 387–398, A. P. Li, D. L. Kaminski, and A. Rasmussen, Substrates of human hepatic cytochrome P450 3A4, Toxicology, 104, 1–8 (1995)
  • Brosen K. Are pharmacokinetic drug interactions with the SSRIs an issue?. Int. Clin. Psychopharmacol. 1996; 11: 23–27, K. T. Kivisto, H. K. Kroemer, and M. Eichelbaum, The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions, Br. J. Clin. Pharmacol., 40, 523–530 (1995); P. Glue and C. Banfield, Psychiatry, psycho-pharmacology and P450s, Hum. Psychopharmacol. Clin. Exp., 11, 97–114 (1996); C. B. Nemeroff, C. L. Devane, and B. G. Pollock, Newer antidepressants and the cytochrome P450 system, Am. J. Psychiatry, 153, 311–320 (1996)
  • Pirnohamed M., Williams D., Madden S., Templeton E., Park B. K. Metabolism and bioactivation of clozapine by human liver microsomes. J. Pharmacol. Exp. Ther. 1995; 272: 984–990, J. Fang, G. B. Baker, R. T. Coutts, and K. F. McKenna, Elucidation of individual cytochrome P450 isoenzymes involved in the metabolism of clozapine, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, October 20–25, 1996, vol. 13, p. 356
  • Quattrochi L. C., Tukey R. H. The human CYPIA2 gene and induction by 3-methylcholantrene. J. Biol. Chem. 1994; 269: 6949–6954
  • Shou M. G., Krausz K. W., Gonzalez F. J., Gelboin H. V. Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expresed human cytochromes P450. Arch. Biochem. Biophys. 1996; 328: 201–207
  • Wu S., Moomaw C. R., Tomer K. B., Falck J. R., Zeldin D. C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxigenase highly expressed in heart. J. Biol. Chem. 1996; 271: 3460–3468
  • Wright M. C., Maurel P., Paine A. J. Induction of cytochrome P4503A by metyrapone in human hepatocyte culture. Hum. Exp. Pathol 1996; 15: 204–204
  • Chen T. L., Ueng T. H., Chen S. H., Lee P. H., Fan S. Z., Liu C. C. Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br. J. Anaesth. 1995; 74: 558–562
  • Hargreaves J. A., Howald W. N., Racha J. K., Levy R. H. Identification of enzymes responsible for the metabolism of phenobarbital. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, October, 20–251996. Vol. 10: 259
  • von Rosentiel N.-A., Adam D. Macrolide antibacterials, drug interactions of clinical significance. Drug Safety 1995; 13: 105–122
  • Barcelo S., Mace C., Pfeifer A., Chipman J. K. Inhibition of human CYPIA2-mediated genotoxicity of 2-amino-3-methylimidazo(4,5f)quinoline (IQ) by suforaphane as a potential mechanism of cancer chemoprevention. ISSX Proceedings, ISSX 1996 European Spring Workshop: Food Toxins and Host Mechanisms Conditioning Toxic Responses, Stiges, Spain, June, 1–41996. Vol. 9: 40
  • WHO Pharmaceuticals Newsletter. 1995; 1, No. 9; WHO Pharm. Newslett., No. 3, 1996, p. 1
  • Watkins P. B., Lown K. S., Fontana R. Effects of diet and medications on CYP3A4 and MDR1 in human small bowel. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 39
  • Madan A., Kramer K. K. Evaluation of new molecular entitites (NME's) as inhibitors of human P450 enzyms. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 49
  • Liu X., Sinz M. W., Woolf T. F., Wang Y., Castagnoli N., Jr. In vitro metabolism of milameline in monkey and human hepatocytes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 216
  • LeClyse E. L., Ribadeneira M. D., Diamond S., Forster J., Huang S.-M., Madan A., Caroll K., Parkinson A. Induction of CYP1A, CYP2A, CYP2B, CYP2C, and CYP3A by various drugs and prototypical inducers in primary cultures of human hepatocytes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 196
  • Clement B., Demesmaeker M. Formation of guanoxabenz from guanabenz in human liver microsomes: A new metabolic marker for CYP1A2. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 225
  • Wong B. K., Goldstein J., Spielberg S. P., Roshmore T. H. Characterisation of an in vitro model for assessing polymorphic metabolism by CYP2C8: Involvement in the mechanism of deficient losartan metabolism. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 236, R. A. Stearns and R. R. Miller, The biotransformation of losartan to its active metabolite E-3174 in human liver microsomes: Inhibition by HMG-CoA reductase inhibitors and non-steroidal antiinflammatory drugs, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, October 20–25, 1996, Vol. 10, p. 385
  • Jung F., Richardson T. H., Griffin K. H., Johnson E. F. Identification of structural elements contributing to high affinity sulphaphenazole binding by CYP2C9. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 239
  • He M. M., Rettie A. E., Trager W. F. Metabolism of sulfinpyrazone by human liver microsomes and cDNA-expressed P450s. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 239
  • Peter R. M., Chen W., Darbyshire J. F., Kunze K. L., Nelson S. D. Inhibition of human CYP2E1 and metabolic intermediate complex formation by isoniazid. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 245
  • Wacher V. J., Wong S., Wong H. T., Benet L. Z. Contribution of CYP3A to selegiline metabolism in rat, and human liver microsomes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 351
  • Fang J., Baker G. B., Coutts R. T., Silverstone P. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 357
  • Camolle G. P., Sharkawi M., Ducharme J., Madan A., Sanzghiri U., Parkinson A., Wainer I. W. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of ifosfamide. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 360
  • Hein N. I., Howell S. R., Ulm E. H. Evaluation of the cytochrome P450 (P450) isozymes involved in the metabolism of TargretinTM, and RXR-selective retinoid. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 364, M. A. Shirley, G. R. Loewen, L. J. Farmer, D. S. Small, and E. H. Ulm, Human metabolism of ALRT 1057 (9-cis-retinoic acid) to 4-oxo-9-cis-retinoic acid: Retention of biological activity and identification of cytochrome P450 isoenzymatic origin, ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, October 20–25, 1996, Vol. 10, p. 365
  • Racha J. K., Mather G. G., Bishop F. E., Kunze K. L., Levy R. H. Involvemement of CYP3A4 and CYP2E1 in the metabolism of felbamate in human liver microsomes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 370
  • Wurm R. M., Dunn J. A., Silver I. S., Patel D. K. In vitro metabolism of bupropion by human liver microsomes and cDNA expressed human cytochrome P450′s. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 371
  • Lang D. H., Böcker R., Schmalix W., Doehmer J. Investigation into the enzymatic reaction pathways responsible for the metabolism of atrazine, terbuthylazine, ametryne, and terbutryne on human liver microsomes and heterologously expressed cytochrome P450′s. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 375
  • Ikeda T., Ishigami M., Komai T., Yamazoe Y., Ohno Y. Inhibition of CYP3A by 3-hydroxy-3-methylglutaryl-CoA (HMGCoA) reductase inhibitors. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 386
  • Grimm S. W., Stams K. R., Aaron E. J. Zafirlukast is a substatrate for CYP2C9 and an inhibitors of CYP2C9 and CYP3A in vitro. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 392
  • Yun C.-H., Park H.-J., Guengerich F. P. Effect of kaempferol on cytochrome P450 activities in human and rat liver microsomes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 259
  • Fitzsimmons M. E., Collins J. M. Selective biotransformation of the HIV protease inhibitors saquinavir by uman small intestinal cytochrome P450 3A4: Potential contribution to high first-pass metabolism. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 400
  • Ridgewell R. E., Mauch K. L., Myhre P. E. In vitro biotransformation of imiquimod catalysed predominantly by human liver CYP1A2 and CYP3A4/5. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 259
  • Prakash C., Kamel A., Cui D. Identification of the human cytochrome P450 responsible for the formation of major metabolites of an antipsychotic drug ziprasidone. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CAUSA, October, 20–251996. Vol. 10: 259
  • Mae T., Hosoe K., Fujii K., Yamashita K., Yamane T., Hidaka T., Ohashi T. In vitro metabolism of a rifamicin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoforms. Xenobiotica 1996; 26: 793–802
  • Fijimaki Y., Hakusu H., Yamazoe Y. Nefiracetam hydroxylation by rat liver microsomes and expressed human cytochrome P450s. Xenobiotica 1996; 26: 821–830
  • Koyama E., Chiba K., Tani M., Ishizaki T. Identification of human cytochrome P450 enzymes isoforms involved in stereoselective metabolism of mianserin enantiomers. J. Pharmacol. Exp. Ther. 1996; 278: 21–30
  • Sahali Sahli Y., Balani S. K., Jin J. H., Baillie T. A. In vitro studies on the metabolic activiation of the furanopyridine L-754,394, a highly potent and selective mechanism based inhibitors of cytochrome P450 3A4. Chem. Res. Toxicol. 1996; 9: 1007–1012
  • Walter B. A. Cytochrome P450-mediated metabolism of the HIV reverse transcriptase inhibitors nevirapine. Course book of the presentations at the IBC's Recent Advances in Drug-Drug Interactions, Washington, DCUSA, Dec., 10-Dec. 111996
  • Shimada T., Hayes C. L., Yamazaki H., Amin S., Hecht S. S., Guengerich F. P., Sutter T. R. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. 1996; 56: 2979–2984
  • Kappers W. A., De Groene E. M., Kleijm L. A., Witkamp R. F., Yweers-Zeilmaker W. M., Feron V. J., Horbach G. J. Inhibition of tolbutamide 4-methylhydroxylation by a series of non-steroidal anti-inflammatory drugs in V79-NH cells expressing human cytochrome P450 2C 10. Xenobiotia 1996; 26: 1231–1239
  • Feierman D. E., Lasker J. M. Metabolism of fentanyl, a synthetic opoid analgesic, by human liver microsomes. Drug Metab. Dispos. 1996; 24: 932–939
  • Zhao X.-J., Yokoyama H., Chiba K., Wan Wimolruk S., Shizaki T. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. J. Pharmacol. Exp. Ther. 1996; 279: 1327–1334
  • Poulsen L., Brosen K., Arendt-Nielsen L., Gram L. F., Elbaek K., Sindrup S. H. Codeine and morphine in extensive and poor metabolisers of sparteine: Pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. 1996; 51: 289–295
  • Laganiere S., Davies R. F., Carignan G., Foris K., Goernert L., Carrier K., Pereira C., McGilverai I. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin. Pharmacol. Ther. 1996; 60: 255–264
  • Black J. Foreword. The Metabolism of Drugs an Other Xenobiotics: Biochemistry of Redox Reactions, B. Testa. Marcel Dekker, New York 1995

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.